1
|
Buschmann C, Unverdorben L, Knabl J, Hutter S, Meister S, Beyer S, Burgmann M, Zati Zehni A, Schmoeckel E, Kessler M, Jeschke U, Eggersmann TK, Mahner S, Kolben T, Ganster F. Placental expression of inflammatory Galectin-12 is associated with gestational diabetes. J Reprod Immunol 2024; 163:104240. [PMID: 38492532 DOI: 10.1016/j.jri.2024.104240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 02/28/2024] [Accepted: 03/11/2024] [Indexed: 03/18/2024]
Abstract
OBJECTIVES Gestational diabetes mellitus (GDM) is a growing health concern. Since members of the galectin-family are identified to play a role in the pathogenesis of GDM, we determined galectin-12 as an essential protein due to its influence in lipolysis and inflammation processes. This study investigates the expression of galectin-12 in the placentas of women with GDM. STUDY DESIGN The study population includes 40 expectant women suffering from GDM and 40 healthy controls. The expression of galectin-12 in the syncytiotrophoblast (SCT) and the extra villous trophoblast (EVT) of the placenta was analyzed by immunohistological staining and double immunofluorescence. Immunoreactivity Score (IRS) was used for evaluation. RESULTS The results demonstrate a significant overexpression of galectin-12 in the nucleus of the SCT and the EVT of placentas with GDM compared to the healthy control group. Additionally, double immunofluorescence visualizes corresponding results with an overexpression of galectin-12 in the extra villous trophoblast of GDM placentas representing maternal cells. CONCLUSION This study identifies galectin-12 to be associated with the process of gestational diabetes mellitus. These findings are in correspondence with the involvement of galectin-12 in inflammatory processes. Maternal BMI and male sex seem to be confounder for the expression of galectin-12 in the nuclear syncytiotrophoblast, but not in other parts of the investigated placental areas. Further investigations are necessary to verify the correlation between gestational diabetes mellitus and the expression of galectin-12 in the placenta and to further elucidate its distinct role.
Collapse
Affiliation(s)
- Christina Buschmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Laura Unverdorben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Julia Knabl
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Stefan Hutter
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Sarah Meister
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Maximiliane Burgmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Alaleh Zati Zehni
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Elisa Schmoeckel
- Department of Pathology, University Hospital, LMU Munich, Germany
| | - Mirjana Kessler
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany; Department of Obstetrics and Gynecology, University Hospital Augsburg, Germany.
| | - Tanja K Eggersmann
- Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, Luebeck, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Franziska Ganster
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|
2
|
Topalov NE, Mayr D, Kuhn C, Leutbecher A, Scherer C, Kraus FBT, Tauber CV, Beyer S, Meister S, Hester A, Kolben T, Burges A, Mahner S, Trillsch F, Kessler M, Jeschke U, Czogalla B. Characterization and prognostic impact of ACTBL2-positive tumor-infiltrating leukocytes in epithelial ovarian cancer. Sci Rep 2023; 13:22620. [PMID: 38114558 PMCID: PMC10730610 DOI: 10.1038/s41598-023-49286-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Accepted: 12/06/2023] [Indexed: 12/21/2023] Open
Abstract
Actin beta-like 2 (ACTBL2) was recently identified as a new mediator of migration in ovarian cancer cells. Yet, its impact on tumor-infiltrating and thus migrating leukocytes (TILs) remains to date unknown. This study characterizes the subset of ACTBL2-expressing TILs in epithelial ovarian cancer (EOC) and elucidates their prognostic influence on the overall survival of EOC patients with special regard to different histological subtypes. Comprehensive immunohistochemical analyses of Tissue-Microarrays of 156 ovarian cancer patients revealed, that a tumor infiltration by ACTBL2-positive leukocytes was significantly associated with an improved overall survival (OS) (61.2 vs. 34.4 months; p = 0.006) and was identified as an independent prognostic factor (HR = 0.556; p = 0.038). This significant survival benefit was particularly evident in patients with low-grade serous carcinoma (OS: median not reached vs. 15.6 months, p < 0.001; HR = 0.058, p = 0.018). In the present cohort, ACTBL2-positive TILs were mainly composed of CD44-positive cytotoxic T-cells (CD8+) and macrophages (CD68+), as depicted by double-immunofluorescence and various immunohistochemical serial staining. Our results provide significant evidence of the prognostic impact and cellular composition of ACTBL2-expressing TILs in EOC. Complementary studies are required to analyze the underlying molecular mechanisms of ACTBL2 as a marker for activated migrating leukocytes and to further characterize its immunological impact on ovarian carcinogenesis.
Collapse
Affiliation(s)
- N E Topalov
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
| | - D Mayr
- Institute of Pathology, Faculty of Medicine, University Hospital, LMU Munich, Munich, Germany
| | - C Kuhn
- Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany
| | - A Leutbecher
- Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
| | - C Scherer
- Department of Medicine I, University Hospital, LMU Munich, Munich, Germany
| | - F B T Kraus
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - C V Tauber
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - S Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - S Meister
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - A Hester
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - T Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - A Burges
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - S Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - F Trillsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - M Kessler
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - U Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
- Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany
| | - B Czogalla
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|
3
|
Meister S, Dreyer EM, Hahn L, Thomann M, Keilmann L, Beyer S, Mayer C, Prins G, Hasbargen U, Mahner S, Jeschke U, Kolben T, Burges A. Risk of postpartum depressive symptoms is influenced by psychological burden related to the COVID-19 pandemic and dependent of individual stress coping. Arch Gynecol Obstet 2023; 308:1737-1748. [PMID: 36482113 PMCID: PMC9735014 DOI: 10.1007/s00404-022-06854-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Accepted: 11/06/2022] [Indexed: 12/13/2022]
Abstract
PURPOSE There are different studies worldwide, which have shown a higher risk of mental disorders due to the COVID-19 pandemic. One aim of this study was to identify influencing factors of the psychological burden related to the COVID-19 pandemic and the impact on the development of postpartum depression. Further, the role of individual stress and coping strategies was analyzed in this context. MATERIALS AND METHODS Between March and October 2020, 131 women in obstetric care at the LMU Clinic Munich completed a questionnaire at consecutive stages during their perinatal period. The times set for the questionnaire were before birth, 1 month, 2 months, and 6 months after birth. The questionnaire was designed to evaluate the psychological burden related to the COVID-19 pandemic. For this a modified version of the Stress and coping inventory (SCI) and the Edinburgh Postnatal Depression Scale (EPDS) was used. RESULTS We could show that the psychological burden related to the COVID-19 pandemic influenced the EPDS score 1, 2 and 6 months after birth. In addition, the prenatal stress and individual coping strategies affected the EPDS and the burden related to the COVID-19 pandemic before and after birth significantly. CONCLUSION An association of the psychological burden related to the COVID-19 pandemic with the risk of developing postpartum depressive symptoms could be shown in this study. In this context, the separation of the partner and the family was recognized as an important factor. Furthermore, the SCI was identified as an effective screening instrument for identifying mothers with an increased risk of postpartum depression. Hereby allowing primary prevention by early intervention or secondary prevention by early diagnosis.
Collapse
Affiliation(s)
- Sarah Meister
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Eva-Maria Dreyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Laura Hahn
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Marilena Thomann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Lucia Keilmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Clarissa Mayer
- Faculty of Psychology, University Würzburg, Würzburg, Germany
| | - Gwendolin Prins
- Faculty of Humanities and Social Sciences, University of Augsburg, Augsburg, Germany
| | - Uwe Hasbargen
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
- Department of Gynecology and Obstetrics, University Hospital Augsburg, 86156 Augsburg, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Alexander Burges
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| |
Collapse
|
4
|
Buschmann C, Unverdorben L, Knabl J, Hutter S, Meister S, Beyer S, Burgmann M, Keilmann L, Zati zehni A, Schmoeckel E, Kessler M, Jeschke U, Mahner S, Kolben T, Ganster F, Burges A. Galectin-10 Expression in Placentas of Women with Gestational Diabetes. Curr Issues Mol Biol 2023; 45:8840-8851. [PMID: 37998731 PMCID: PMC10670440 DOI: 10.3390/cimb45110554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 10/30/2023] [Accepted: 10/30/2023] [Indexed: 11/25/2023] Open
Abstract
Galectins are known to play an important role in immunoregulatory processes and autoimmune diseases. Galectin-10 is a cytoplasmic protein of human eosinophils and is involved in various eosinophilic diseases. Since increased galectin expression is already detected in the placentas of mothers with gestational diabetes mellitus (GDM), this study focuses on the specific role of galectin-10 and hints at consequences for the diagnosis and therapeutic options of GDM. It is hypothesized that the difference in galectin-10 expression will raise the pathophysiological understanding of gestational diabetes. The study population consists of 80 women: 40 healthy mothers and 40 women suffering from gestational diabetes mellitus. The expression of galectin-10 was analyzed in the syncytiotrophoblast (SCT) and the decidua of the placenta via immunohistochemistry and immunofluorescence double staining. The immunoreactivity score (IRS) was used for evaluation. The results in this study were significant for an overexpression of galectin-10 in GDM placentas compared with the control group. The syncytiotrophoblast showed overexpression in the nucleus and the cytoplasm, whereas expression of galectin-10 in the decidua was significant in the cytoplasm only. This study identified the expression changes in galectin-10 in placental tissue between healthy and GDM mothers and intensified the understanding of gestational diabetes. Assuming that gestational diabetes mellitus is involved in inflammatory processes, galectin-10 might play a role in the development and maintenance of GDM. Further investigation is required to strengthen these findings.
Collapse
Affiliation(s)
- Christina Buschmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Laura Unverdorben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Julia Knabl
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Stefan Hutter
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Sarah Meister
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Maximiliane Burgmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Lucia Keilmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Alaleh Zati zehni
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Elisa Schmoeckel
- Department of Pathology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Mirjana Kessler
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
- Department of Obstetrics and Gynecology, University Hospital Augsburg, 86156 Augsburg, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Franziska Ganster
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| | - Alexander Burges
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany
| |
Collapse
|
5
|
Upadhyay R, Elguindy AN, Sengupta S, Wang K, Beyer S, Thomas EM, Raval R, Palmer JD. Initial Report of Boswellia Serrata for Management of Cerebral Radiation Necrosis after Stereotactic Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys 2023; 117:S172-S173. [PMID: 37784429 DOI: 10.1016/j.ijrobp.2023.06.639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Radiation necrosis (RN) is a concerning late toxicity after radiation therapy (RT) for brain metastases. Oral corticosteroids are the mainstay of management; however, they are not optimal for long-term use given multiple side effects and drug interactions, particularly with the emergence of immunotherapy for several cancers. Boswellia serrata (BS) is an over-the-counter supplement used for its anti-inflammatory properties and has been recently shown to reduce cerebral edema after brain RT. We evaluated the response rates with BS in a series of patients with brain metastases treated with stereotactic radiosurgery (SRS) who developed RN. MATERIALS/METHODS We included patients who developed RN after SRS for brain metastases at our institution from 2020-2022 and were treated with BS. Patients were prescribed over the counter BS 4.2-4.5g daily in divided doses. Follow-up MRI imaging was obtained every 2-3 months after starting BS. Response was assessed using Response Assessment in Neuro-Oncology (RANO) criteria. Primary endpoint was ≥25% decrease in edema volume on T2-FLAIR MRI from baseline. Patients were censored if they had tumor progression or repeat RT to necrotic area, or death. Kaplan-Meier curves were used for survival estimates. RESULTS A total of 50 patients received BS for Grade 1-3 CTCAE v5.0 RN (G1 = 11, G2 = 36, and G3 = 3). Median age was 62.8 years (range 36.9 - 50) and median RT dose was 24 Gy in 3 fractions. Median time to RN after SRS was 10 months(m). Median follow-up after starting BS was 6m and 40 patients had at least 1 follow up MRI available to evaluate response. The best response was complete response (CR) in 15% patients and partial response (PR) in 40% while 35% had stable disease (SD) and 10% had progressive disease. Median time to CR was 9m (6-12m) and PR was 6m (3-12m). Percentage of patients who had any response (CR or PR) at 3, 6, 9 and 12 months was 25%, 60%, 43% and 50%, respectively. 56% patients had symptomatic RN, of which 35.7% had improvement in symptoms with BS alone, while 64% required steroid use. Overall, median duration of response in patients with CR, PR or SD was 7.5m(range 2-31m). Salvage treatment for RN was steroids (33), surgery (4), Bevacizumab (5) or hyperbaric oxygen therapy (1). No patients had any CTCAE grade 3 or higher toxicities. 3 patients (6%) had any side-effects all of whom had Grade 1-2 gastrointestinal intolerance or diarrhea. 2 patients stopped treatment due to enrolment on an immunotherapy clinical trial. Overall, 39 patients remained on BS at last follow-up or death. CONCLUSION We observed >50% response rates with use of BS in our cohort of patients with Grade 1-3 RN after SRS. More than 1/3rd patients with symptomatic RN were able to avoid long-term steroid use. BS is an easily available over-the-counter drug that appears to be a safe and promising treatment option for RN, and can potentially decrease steroid dependence in these patients, reducing the risk of several side-effects. Further prospective studies to compare Boswellia with placebo is warranted.
Collapse
Affiliation(s)
| | - A N Elguindy
- The James Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
| | - S Sengupta
- Department of Neurology, University of Cincinnati, Cincinnati, OH
| | - K Wang
- Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E M Thomas
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Raval
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| |
Collapse
|
6
|
Dohm AE, Upadhyay R, Tang JD, Oliver DE, Perez BA, Rosenberg SA, Yu HHM, Palmer JD, Beyer S, Owen D, Ahmed KA. Upfront Osimertinib Alone vs. Osimertinib and Radiotherapy for the Treatment of EGFR-Positive NSCLC Brain Metastases: A Multi-Institutional Series. Int J Radiat Oncol Biol Phys 2023; 117:e100-e101. [PMID: 37784626 DOI: 10.1016/j.ijrobp.2023.06.869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Given the increased brain penetrance of osimertinib, the role of upfront radiotherapy (RT) has been questioned for the management of patients with EGFR+ NSCLC brain metastases (BM). We conducted a multi-institutional review of patients with EGFR+ NSCLC treated with upfront osimertinib or osimertinib in combination with RT for new or progressing BM. MATERIALS/METHODS Our multi-institutional analysis included 128 patients with 714 BM treated between 2013 and 2022. Two BM treatment groups were evaluated: (1) upfront osimertinib alone (n = 66) and (2) osimertinib + RT [whole brain radiation therapy or stereotactic/fractionated radiosurgery (SRS/FSRT)] prior or concurrently with osimertinib (n = 62)]; both groups began treatment within 2 months of BM diagnosis. Time-to-event analysis was conducted with the Kaplan-Meier (KM) method, and outcomes included intracranial control (IC) [both local and distant], intracranial progression free survival (IPFS), and overall survival (OS). A Cox proportional hazards model was utilized for multivariate analysis (MVA). RESULTS Median follow-up from BM diagnosis was 33.9 months (0.13-76.2 months). No differences in age (p = 0.46), sex (p = 0.72), DS-GPA (p = 0.08), KPS (p = 0.57), number of BM (p = 0.19) or volume of BM (p = 0.45), RT dose (p = 0.45), number of systemic metastases (p = 0.88), and patients symptomatic at presentation (p = 1.0) were noted. Prior treatment of BM was more common in the osimertinib + RT group (50% osimertinib + RT and 27% osimertinib; p = 0.01). The 12-month KM rates for osimertinib vs osimertinib + RT groups for IC were 72% vs 73% (p = 0.33); IPFS 53% vs 66% (p = 0.007); and OS 65% vs 80% (p = 0.025). On MVA, higher KPS (p = 0.002) was associated with increased OS and no extracranial metastasis with increased OS (p = 0.01) and IPFS (p = 0.001). MVA showed no association between osimertinib vs osimertinib + RT for IC, IPFS, or OS. Of the 66 patients treated with upfront osimertinib, 18 patients (27%) with 31 lesions eventually required RT for intracranial progression with the majority 72% being treated with SRS/FSRT at median of 13.5 months (1-22 months) following the start of osimertinib. CONCLUSION This study suggests that upfront osimertinib alone may provide sufficient intracranial control to allow RT to be deferred until further intracranial progression in select patients. Prospective trials are warranted to further guide treatment.
Collapse
Affiliation(s)
- A E Dohm
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - R Upadhyay
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Tang
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - D E Oliver
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - B A Perez
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - S A Rosenberg
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - H H M Yu
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - D Owen
- The Ohio State University, Columbus, OH
| | - K A Ahmed
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| |
Collapse
|
7
|
McCalla A, Upadhyay R, Perlow HK, Raval R, Beyer S, Blakaj DM, Grecula JC, Palmer JD, Thomas EM. WBRT is Associated with Higher Rates of Hematologic Toxicity than Stereotactic Radiosurgery in Brain Metastasis Patients. Int J Radiat Oncol Biol Phys 2023; 117:e137-e138. [PMID: 37784705 DOI: 10.1016/j.ijrobp.2023.06.944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Whole brain radiotherapy (WBRT) has historically been a standard of care in patients with multiple brain metastases. Studies show that WBRT may be associated with a transient detriment in hematological parameters because of exposure to a larger proportion of circulating lymphocytes, platelets and hematopoietic cells within the bone marrow of the cranium. In this study, we tested the hypothesis that stereotactic radiotherapy (SRS) may cause reduced hematologic toxicity in patients compared to WBRT. MATERIALS/METHODS We retrospectively identified 100 patients treated for brain metastasis, with either SRS or WBRT from 2016 to 2019, and queried their pre- and post-treatment hematological parameters including hemoglobin, total white blood cell (WBC), absolute neutrophil count (ANC), absolute lymphocyte count, and platelet count. CTCAE v5.0 was used for grading hematologic toxicities. Serial values were compared by treatment type and controlled for age, gender, and systemic therapy. Student t-test was used for intergroup comparison and p-value <0.05 was considered significant. RESULTS Of 100 patients, median brain metastases was 3 (range 1-22), 51 received SRS and 49 received WBRT. We observed that patients treated with WBRT had a significantly higher post-treatment reduction in platelet count (-51.2 vs 9.8; p = 0.001) and higher incidence of any grade thrombocytopenia (31.2% vs 10%; p = 0.019) compared to patients treated with SRS. We also noted that compared with SRS, WBRT was associated with a higher post-treatment reduction in circulating lymphocytes (-0.80 vs 0.14; p = 0.071) and higher incidence of G3+ lymphopenia (43.2% vs 22.2%; p = 0.07). Numerical incidence of any G3+ hematological toxicity was also higher in the WBRT group but the difference was not statistically significant (40% vs 28%, p = 0.162). Hemoglobin count, WBC, and ANC were not meaningfully different pre- and post-treatment for either group. CONCLUSION WBRT results in an increased amount and duration of radiation exposure to circulating intracranial blood volume. In our study, patients treated with WBRT experienced higher rates of clinically significant lymphopenia & thrombocytopenia compared to patients treated with SRS. In addition to the cognitive benefits of SRS compared to WBRT, there may be significant hematologic benefits as well. Further studies are warranted to clarify and validate these findings.
Collapse
Affiliation(s)
- A McCalla
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | | | - H K Perlow
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Raval
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - D M Blakaj
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J C Grecula
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E M Thomas
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| |
Collapse
|
8
|
Perlow HK, Matsui JK, Ewing A, Cadieux C, Blakaj DM, Beyer S, Thomas EM, Grecula JC, Raval R, Palmer JD. Volumetric Modulated Arc Therapy Craniospinal Irradiation Utilizing a Vertebral Body Sparing Approach: A Toxicity Analysis. Int J Radiat Oncol Biol Phys 2023; 117:S174. [PMID: 37784434 DOI: 10.1016/j.ijrobp.2023.06.642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Craniospinal irradiation (CSI) is indicated for adult patients diagnosed with leptomeningeal disease (LMD). Proton-based vertebral-body-sparing (VBS) CSI has been explored with pediatric patients to minimize hematologic toxicity; however, utilization of VBS in an adult population is limited. A recent phase II trial (Yang et al, JCO 2022) has shown efficacy of proton-based CSI to treat non-small cell lung and breast cancer with LMD. We hypothesize that VBS-CSI utilizing volumetric modulated arc therapy (VMAT) could also effectively reduce dose to vertebral bodies and surrounding organs-at-risk (OARs), minimizing toxicity for adult patients with LMD and comparing favorably to proton-based CSI. MATERIALS/METHODS Consecutive patients with leptomeningeal disease received VMAT VBS-CSI, 30 Gy in 10 fractions, as a part of a prospective registry. Full VMAT arcs for the brain fields matched to two spine isocenters for the upper and lower spine were created utilizing limited posterior arcs. The PTV was created with margins of 3mm uniformly around the brain contour and 7mm around the spinal canal. To further decrease the vertebral body dose, an avoid entry and exit contour was created. This structure was a margin on the PTV anteriorly designed to carve dose out of the vertebral bodies while still maintaining coverage to the PTV. Acute toxicity data were collected using Common Terminology Criteria for Adverse Events (CTCAE) v5 and was defined as toxicity occurring within 30 days of treatment conclusion. RESULTS Ten adult patients were treated in this cohort. All patients completed radiation treatment. One patient experienced Grade 2 neutropenia with the remaining nine experiencing Grade 1 hematologic toxicity (three Grade 1 pancytopenia, six Grade 1 thrombocytopenia). Three patients experienced Grade 2 gastrointestinal toxicity (Grade 2 nausea, Grade 2 esophagitis, Grade 2 esophagitis/Grade 2 diverticulitis) with the remaining seven experiencing Grade 1 nausea. No patient experienced Grade 3+ toxicities in this cohort. One patient experienced a 5-day delay in systemic therapy initiation due to neutropenia; otherwise, all patients planned for systemic therapy started without delay. CONCLUSION VMAT VBS-CSI is an effective technique to reduce dose to surrounding OARs and vertebral bodies. In this study, VMAT VBS-CSI led to acceptable toxicity compared to patients treated with proton CSI on a phase 2 clinical trial. An NRG phase 3 clinical trial may be developed to evaluate the efficacy of proton-based CSI for patients with LMD. However, these data show how VMAT VBS-CSI may be an acceptable alternative for centers without proton therapy capabilities. Given its promising early results, future prospective evaluation of the technique is warranted.
Collapse
Affiliation(s)
- H K Perlow
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J K Matsui
- The Ohio State University College of Medicine, Columbus, OH
| | - A Ewing
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - C Cadieux
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - D M Blakaj
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E M Thomas
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J C Grecula
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Raval
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| |
Collapse
|
9
|
Upadhyay R, Palmer JD, Perlow HK, Schoenhals J, Ghose J, Rajappa P, Blakaj DM, Beyer S, Grecula JC, Sim AJ, Hardesty D, Elder JB, Chakravarti A, Thomas EM, Raval R. Patient-Reported Cognitive Outcomes and Survival after Stereotactic Radiosurgery for 15 or More Brain Metastases. Int J Radiat Oncol Biol Phys 2023; 117:e153-e154. [PMID: 37784741 DOI: 10.1016/j.ijrobp.2023.06.977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Overall survival (OS) in metastatic cancer patients has been improving with continued advancements, necessitating greater attention to treatment related toxicities. Patients with ≥ 15 brain metastases (BM) continue to be treated with whole brain radiation therapy (WBRT), despite poor neurocognitive outcomes. We analyzed our institutional experience of treating these patients with stereotactic radiosurgery (SRS), with the aim of evaluating safety, cognitive outcomes, and survival metrics. MATERIALS/METHODS Patients who received SRS for ≥ 15 BMs in 1-5 fractions from 2014-2022 using the previously described single isocenter multi-target technique were included. Cognitive outcomes were objectively evaluated using serial Patient-Reported Outcome Measurement Information System (PROMIS) scores. Kaplan-Meier method was used for survival analysis and log-rank test was used for intergroup comparisons. RESULTS A total of 118 patients underwent 124 courses of LINAC-based SRS. The mean and median number of lesions treated per patient was 24.8 and 20, respectively (range 15 - 94). Most common primary histologies were lung (47.6%), melanoma (21.0%), and breast (14.5%). The median SRS dose was 24 Gy (range 18 - 30 Gy) with 87.9% receiving 3 fraction SRS. At the time of SRS, 19.4% patients had received prior WBRT and 24.2% had received at least one prior SRS course. The rate of any grade radiation necrosis (RN) and ≥ grade 3 RN were 15.3% and 3.2% respectively. New onset seizures were seen in 2.4%, alopecia in 2.4%, and subjective cognitive decline in 4% of patients. Median follow-up by reverse Kaplan-Meier method was 17.8 months (m). Cognitive data was available for 38 patients. Mean PROMIS scores at baseline, 3m, 6m and 9m after SRS were 32.0, 31.6, 30.4 and 28.7 out of 40, respectively. When longitudinal trends were available, 25 of 31 patients had a stable or improved PROMIS score. The 12m local control was 97.6%. Cumulative incidence of distant intracranial failure was 79.2%. One year freedom from neurological death, leptomeningeal disease, and salvage WBRT were 85.6%, 87.6% and 71.7% respectively. Median OS from brain metastases diagnosis was 11.3m (95% CI 7.2m - 15.3m) overall, while it was 9.2m (6.5 - 11.8m) after excluding patients who had prior WBRT or SRS (n = 79). One-year survival was 40% from diagnosis and 38.7% from SRS. On Cox regression analysis, prior WBRT (p = 0.002), higher KPS (p = 0.050), systemic therapy after SRS (p<0.001), and controlled extracranial disease (p = 0.007) predicted for improved OS. CONCLUSION We present here the largest study evaluating SRS for patients with ≥ 15 BMs. We found that SRS was safe, had favorable cognitive outcomes, and comparable survival outcomes to contemporary studies evaluating WBRT in this patient population. Treatment-naïve patients had a median survival of > 6 months, long enough to benefit from cognitive sparing with SRS. Our study supports further randomized studies comparing SRS and memory avoidance WBRT approaches for patients with ≥ 15 BMs.
Collapse
Affiliation(s)
- R Upadhyay
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - H K Perlow
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J Schoenhals
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - J Ghose
- The Ohio State University, Columbus, OH
| | - P Rajappa
- Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH
| | - D M Blakaj
- James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J C Grecula
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - A J Sim
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - D Hardesty
- Department of Neurosurgery, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J B Elder
- The James Cancer Hospital, Columbus, OH
| | - A Chakravarti
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - E M Thomas
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Raval
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| |
Collapse
|
10
|
Perlow HK, Nalin A, Ritter A, Addington M, Ward A, Liu M, Nappi C, Blakaj DM, Beyer S, Thomas EM, Grecula JC, Raval R, Kotecha R, Boulter D, Dawson E, Zoller W, Palmer JD. Advancing beyond the Hippocampus to Preserve Cognition for Patients with Brain Metastases: Dosimetric Results from a Phase 2 Trial of Memory-Avoidance Whole Brain Radiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e145-e146. [PMID: 37784722 DOI: 10.1016/j.ijrobp.2023.06.960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Recent advances to preserve neurocognitive function in patients treated for brain metastases include stereotactic radiosurgery (SRS), hippocampal avoidance whole brain radiation therapy (HA-WBRT), and memantine administration. However, 23% of patients receiving HA-WBRT and memantine on NRG-CC001 still experienced executive function deterioration at 4 months, with 12% experiencing total recall and delayed recognition deterioration at 6 months. The hippocampus, corpus callosum, fornix, and amygdala are key neurocognitive substructures with a low propensity for brain metastases. Herein, we report our preliminary experience using an advanced "memory-avoidance" WBRT (MA-WBRT) approach sparing these substructures for patients with multiple (>15) brain metastases. MATERIALS/METHODS Ten consecutive patients treated with MA-WBRT on a phase 2 clinical trial (OSU-21074) were reviewed. In each patient, the hippocampi, amygdalae, corpus callosa, and fornix were contoured. Patients were not eligible for MA-WBRT if they had metastases in these substructures. A memory- avoidance region created using a 5mm volumetric expansion around these substructures. Hotspots were avoided in the hypothalamus and pituitary gland. Dose constraints for these avoidance structures were modeled after NRG CC-001 and include a D100% ≤ 9 Gy and a D0.03 cc ≤ 16 (acceptable to 20 Gy). Coverage of brain metastases was prioritized over memory avoidance dose constraints. Linac-based volumetric modulated arc therapy (VMAT) plans were generated for a prescription dose of 30 Gy in 10 fractions. RESULTS On average, the memory avoidance structure volume was 37.1 ccs (Range: 25.2-44.6 ccs), occupying 2.5% of the entire whole brain target volume. All treatment plans met the D100% dose constraint, and 8/10 plans met the D0.03cc constraint, with priority given to tumor coverage for the remaining 2 cases. VMAT spared the memory avoidance structures with a median dose range of 10.8-14.2 Gy and a maximum dose (D0.03cc) range of 15.6-22.7 Gy. The mean dose to the memory avoidance structures was 12.7 Gy (Range: 11.5-13.8 Gy). Target coverage (D98% > 25 Gy) and homogeneity (D2% ≤ 37.5 Gy) were achieved for all plans. CONCLUSION Modern VMAT techniques allow for sparing of the hippocampus, amygdala, corpus callosum, and fornix with good target coverage and homogeneity. Prospective quality of life and cognitive data including are being collected and include the Functional Assessment of Cancer Therapy - Brain (Fact-Br), Hopkins Verbal Learning Test (HLVT-R), Trail Making Test A/B (TMT-A/B) and Controlled Oral Word Association Test (COWAT). After enrollment is completed, these data will be evaluated to assess the efficacy of MA-WBRT to mitigate declines in quality of life and cognition after whole brain radiation.
Collapse
Affiliation(s)
- H K Perlow
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - A Nalin
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - A Ritter
- The Ohio State University, Columbus, OH
| | - M Addington
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - A Ward
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - M Liu
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - C Nappi
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - D M Blakaj
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E M Thomas
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J C Grecula
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Raval
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - R Kotecha
- Florida International University, Herbert Wertheim College of Medicine, Miami, FL
| | - D Boulter
- Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E Dawson
- Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - W Zoller
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| |
Collapse
|
11
|
Dibs K, Facer BD, Palmer JD, Pan J, Raval R, Thomas EM, Cochran ER, Beyer S, Grecula JC, Ayan AS, Zoller W, Christ D, Scharschmidt T, Elder JB, Bourekas E, Xu D, Chakravarthy V, Elguindy AN, Chakravarti A, Blakaj DM. Vertebral Compression Fracture Post Spine Stereotactic Body Radiotherapy: The Role of Vertebral Endplate. Int J Radiat Oncol Biol Phys 2023; 117:e99. [PMID: 37786229 DOI: 10.1016/j.ijrobp.2023.06.866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Maintaining hydrostatic pressure -via Pascal's Principle- between vertebral bodies is essential to decrease the chance of vertebral compression fracture (VCF). Vertebral endplates (EP) play an essential role in this matter through maintaining the mechanical environment as well as the proper nutrition of avascular discs. The purpose of this study is to establish the correlation of VCF with disrupted EP by tumor involvement. MATERIALS/METHODS A retrospective analysis of de novo spine metastases treated with stereotactic body radiotherapy (SBRT) between 2013-2019. Patients (pts) with previous surgical intervention were excluded. VCF defined as new or progression of existing loss of vertebral body height. The vertebral EP region defined in relation to the vertebral body as superior EP vs inferior EP. Kaplan-Meier curves used to analyze the variables. A multivariate proportional hazard model used to assess the risk of all covariates. RESULTS A total of 111 pts were treated with SBRT with a median dose of 27 Gy (10-35 Gy). Median follow-up was 18 months (1.2-107). The median age was 60 years (24-87) and 59 were males (53%) and 52 were females (47%). The median body mass index (BMI) was 27 kg/m2 (16-47). Almost 9 pts diagnosed with osteoporosis prior radiation. Twelve pts received prolonged steroids. Twenty pts received bisphosphonate and 8 pts received denosumab. The median PTV was 50cc (8-465) and median Conformity Index was 1.05 (0.42-1.4). Almost 75% of pts received >95% of the dose covering 100% of the PTV. The most common histopathologies were renal cell carcinoma (25%), lung (13%) and breast (11%). Most of the pts (77%) had SINS score of 7 or less. 48 pts (43%) had either superior or inferior EP disruption secondary to the tumor at the time of radiation. Twenty pts (18%) had both superiorly and inferiorly disrupted EP. Around 20 pts (18%) developed VCF. The median time to VCF was 5.2 months (1.1-57.4). The one-year cumulative incidence of VCF was 18%. The 1-year cumulative incidence of VCF with either superiorly and/or inferiorly disrupted EP was 29% vs 6%, p value <0.001. The 1-year cumulative incidence of VCF with both superiorly and inferiorly disrupted EP was 57% vs 7% (p value <0.001). The median time to VCF was earlier in pts with both disrupted EP (2.4 months vs 5.7 months, p value <0.05). Other risk factors like SINS score of >7 and local recurrence (LR) associated with higher risk of VCF. On multivariate analysis, LR (HR 8.2 [CI 2.4-28, p- value <0.001]), tumor disrupting the EP (HR 4.5 [CI 1.3-16, p-value<0.018]) and SINS score of seven and above (HR 1.7 [CI 1.3-2.25, p-value <0.001]) correlated with the VCF risk. CONCLUSION In this retrospective analysis, tumor disrupting the EP, disease recurrence and high SINS score increased the risk of VCF. Cement augmentation either prophylactically or immediately following SBRT is currently being studied in a prospective trial within our institution.
Collapse
Affiliation(s)
- K Dibs
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - B D Facer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J Pan
- The Ohio State University Wexner Medical Center, Center for Biostatistics, Columbus, OH
| | - R Raval
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E M Thomas
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - E R Cochran
- The Ohio State University Hospital, Columbus, OH, United States
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J C Grecula
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - A S Ayan
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - W Zoller
- The James Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
| | - D Christ
- The Ohio State University Wexner Medical Center, Department of Radiation Oncology, Columbus, OH
| | | | - J B Elder
- The James Cancer Hospital, Columbus, OH
| | - E Bourekas
- The Ohio State University Wexner Medical Center, Department of Neuroradiology, Columbus, OH
| | - D Xu
- Department of neurosurgery, The James Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
| | - V Chakravarthy
- Department of neurosurgery, The James Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
| | - A N Elguindy
- The James Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
| | - A Chakravarti
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - D M Blakaj
- James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH
| |
Collapse
|
12
|
Kumar A, Rajasekera P, Becker V, Biehn S, Pérez-Soto B, Beyer S, McElroy J, Becker A, Johnson B, Cui T, Sebastian E, Grosu A, Lindert S, Bell EH, Manring H, Haque J, Chakravarti A. Hypoxia-Inducible Transgelin-2 Confers Treatment Resistance through Activation of PI3K/Akt/GSK3β Pathway in Glioblastoma. Int J Radiat Oncol Biol Phys 2023; 117:e121. [PMID: 37784671 DOI: 10.1016/j.ijrobp.2023.06.910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Glioblastoma (GBM) patients with wild-type IDH experience worse survival response to the standard treatment of surgery followed by radiation therapy (RT) and temozolomide (TMZ) chemotherapy compared to their mutant IDH counterparts. This treatment has remained relatively ineffective partly due to the highly invasive phenotype of GBM leading to therapeutic resistance and tumor recurrence. Hypoxia is one of the key characteristic features of GBM which results in cancer metastasis and confers treatment resistance. Therefore, it is paramount to identify targets to help overcome hypoxia-induced treatment resistance in glioblastoma. Our lab has identified transgelin-2 (TAGLN2) to be significantly upregulated in IDH-wt GBM through multiple molecular profiling studies. This study aims to understand the mechanisms by which TAGLN2 confers treatment resistance for developing additional treatments for GBM. Additionally, active drug development efforts are also underway to target TAGLN2 for circumventing these therapeutic resistance mechanisms for effective GBM therapy. MATERIALS/METHODS RNAi-mediated TAGLN2 knockdown (KD) approach was employed to assess the functions of TAGLN2 in GBM patient-derived xenograft (PDX) cell lines. Series of in vitro functional assays were performed to assess the role of TAGLN2 in these cell lines. Cell proliferation, invasion ± RT and/or TMZ were assessed by MTS and Trans-well invasion assays. Subsequently, WB analysis of oncogenic signaling pathways was performed following Transgelin-2 KD. Co-IP assays and Biacore/SPR analyses were performed to study the binding affinity and kinetics for the interaction of PTEN with TAGLN2. Further, cells were intracranially implanted in nude mice to assess the role of TAGLN2 on tumor growth in vivo. RESULTS Conditional KD of TAGLN2 reduces cell proliferation, survival and invasive potential of GBM PDX cell lines. TAGLN2 KD also improved the sensitivity of these cells to both TMZ and radiation in vitro, as assessed by proliferation, survival, clonal expansion, and invasion. Histopathological studies of human GBM tumors and mouse xenograft tumors showed elevated expression of TAGLN2 in the peri-necrotic region of the tumors indicating that TAGLN2 protein level was upregulated by hypoxia. We also show that TAGLN2 is induced in hypoxic microenvironments with GBM PDX cell lines and its overexpression may enhance cellular resistance towards conventional therapy. Subsequently, we also show that hypoxia-induced TAGLN2 activates the PI3K/Akt oncogenic pathway through binding and inhibition of PTEN. Finally, in vivo data using an orthotopic xenograft mouse model shows reduction of tumor growth with knockdown of TAGLN2. CONCLUSION Our in vitro and in vivo xenograft studies suggest that TAGLN2 confers treatment resistance to GBM contributing to tumor recurrence. Altogether, TAGLN2 may serve as a potential therapeutically vulnerable target in GBM specifically through its role in cell survival and invasion.
Collapse
Affiliation(s)
- A Kumar
- Department of Radiation Oncology, Arthur G. James Hospital Ohio State Comprehensive Cancer Center, Columbus, OH
| | - P Rajasekera
- Department of Radiation Oncology, Arthur G. James Hospital/The Ohio State University Wexner Medical Center/Comprehensive Cancer Center, Columbus, OH
| | - V Becker
- 1Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH
| | - S Biehn
- Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH
| | - B Pérez-Soto
- Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J McElroy
- The Ohio State University, Center for Biostatistics, Department of Biomedical Informatics, Columbus, OH
| | - A Becker
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - B Johnson
- The Ohio State University, Columbus, OH
| | - T Cui
- The Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA
| | - E Sebastian
- Department of Radiation Oncology, Arthur G. James Hospital/The Ohio State University Wexner Medical Center/Comprehensive Cancer Center, Columbus, OH
| | - A Grosu
- German Cancer Consortium (DKTK), Partner Site Freiburg, Heidelberg, Germany
| | - S Lindert
- Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH
| | - E H Bell
- Administrative Director, Neuroscience Research Institute, Columbus, OH
| | - H Manring
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - J Haque
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - A Chakravarti
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| |
Collapse
|
13
|
Vattai A, Kremer N, Meister S, Beyer S, Keilmann L, Buschmann C, Corradini S, Schmoeckel E, Kessler M, Mahner S, Jeschke U, Hertlein L, Kolben T. Increase of the T-reg-recruiting chemokine CCL22 expression in a progressive course of cervical dysplasia. J Cancer Res Clin Oncol 2023; 149:6613-6623. [PMID: 36792811 DOI: 10.1007/s00432-023-04638-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Accepted: 02/06/2023] [Indexed: 02/17/2023]
Abstract
PURPOSE An increasing infiltration of FoxP3-positive T-regs is associated with a higher grade of cervical intraepithelial neoplasia. The T-reg-recruiting chemokine CCL22 is expressed in various tumour entities. Aim of our study was to investigate the role of CCL22 in the progression and regression of cervical intraepithelial neoplasias, especially in patients with intermediate cervical intraepithelial neoplasias (CIN II). Furthermore, our aim was to characterize the CCL22-producing cells and explore the role of innate immunity in the process of cells recruitment. METHODS CCL22 expression was analyzed immunohistochemically in 169 patient samples. The immunoreactive score as well as the median numbers of positive cells were calculated in each slide and correlated with the histological CIN grade and FoxP3 expression. Additionally, CD68/CCL22 as well as CD68/PPARγ and CD68/FoxP3 expression were examined by double immunofluorescence. Statistical analysis was performed by SPSS 26. RESULTS A significantly higher expression of epithelial CCL22 in CIN II with progression in comparison to CIN II with regression (p = 0.006) could be detected. CCL22 was correlated with FoxP3 (Spearman's Rho: 0.308; p < 0.01). In 88%, CCL22-positive cells were positive for CD68, and 71% of CD68-positive macrophages expressed PPARγ. Colocalization of CD68 and FoxP3 was detected in 12%. CONCLUSION We could demonstrate that increased expression of CCL22, mainly produced by macrophages, correlates with elevated potential of malignancy. CCL22 expression could act as a predictor for regression and progression in cervical intraepithelial neoplasia, and it may help in the decision process regarding surgical treatment versus watchful waiting strategy in order to prevent conisation-associated risks. Furthermore, our findings support the potential of CCL22-producing cells as a target for immune therapy in cervical cancer patients.
Collapse
Affiliation(s)
- Aurelia Vattai
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377, Munich, Germany.
- Kinderwunsch Centrum Muenchen, 81241, Munich, Germany.
| | - Nadine Kremer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377, Munich, Germany
| | - Sarah Meister
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377, Munich, Germany
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377, Munich, Germany
| | - Lucia Keilmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377, Munich, Germany
| | - Christina Buschmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377, Munich, Germany
| | - Stefanie Corradini
- Department of Radiation Oncology, University Hospital, LMU Munich, 81377, Munich, Germany
| | - Elisa Schmoeckel
- Institute of Pathology, Faculty of Medicine, LMU Munich, 80337, Munich, Germany
| | - Mirjana Kessler
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377, Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377, Munich, Germany
- Department of Obstetrics and Gynecology, University Hospital Augsburg, 86156, Augsburg, Germany
| | - Linda Hertlein
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377, Munich, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377, Munich, Germany
| |
Collapse
|
14
|
Beyer S, Trillsch F, Kost B, Burges A, Mahner S, Kolben T. Publisher Erratum: Langer Leidensweg bei Endometriose. MMW Fortschr Med 2023; 165:66. [PMID: 36703076 DOI: 10.1007/s15006-023-2298-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- Susanne Beyer
- Klinik und Poliklinik für Frauenheilkunde und GeburtshilfeLMU Klinikum, Marchioninistr. 15, 81377, München, Deutschland
| | - Fabian Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum Großhadern der LMU München, Marchioninistr. 15, 81377, München, Deutschland
| | - Bernd Kost
- Klinik und Poliklinik für Frauenheilkunde und GeburtshilfeLMU Klinikum, Marchioninistr. 15, 81377, München, Deutschland
| | - Alexander Burges
- Klinik und Poliklinik für Frauenheilkunde und GeburtshilfeLMU Klinikum, Marchioninistr. 15, 81377, München, Deutschland
| | - Sven Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe der LMU, Klinikum Großhadern, Marchioninistraße 15, 81377, München, Deutschland
| | - Thomas Kolben
- Klinik und Poliklinik für Frauenheilkunde und GeburtshilfeLMU Klinikum, Marchioninistr. 15, 81377, München, Deutschland
| |
Collapse
|
15
|
Keilmann L, Beyer S, Meister S, Jegen M, Buschmann C, Schröder L, Keckstein S, Jeschke U, Burges A, Mahner S, Trillsch F, Kost B, Kolben T. Trends among patients with endometriosis over a 7-year period and the impact of the COVID-19 pandemic: experience from an academic high-level endometriosis centre in Germany. Arch Gynecol Obstet 2023; 307:129-137. [PMID: 36068363 PMCID: PMC9449266 DOI: 10.1007/s00404-022-06730-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Accepted: 07/28/2022] [Indexed: 02/02/2023]
Abstract
PURPOSE Endometriosis is known to be an underestimated disease. Lately the awareness of the disease seems to have improved. Aim of this analysis is to provide an overview of the development of treatment of patients diagnosed with endometriosis. This includes a special scope on implications of the COVID-19 pandemic since in multiple settings postponed treatments resulting in negative impact on prognosis were reported. MATERIALS AND METHODS We analysed the development of numbers of patients treated for endometriosis in an academic centre within a 7-year period, 01/2015-12/2021, performing a systematic analysis of ICD-10-Codes from our computer system used in clinical routine. RESULTS Treatment numbers increased over the past 7 years, i.e., 239 treated cases in 2015 vs. 679 in 2021. Following restrictions for outpatient evaluation and surgical capacity at our centre, during COVID-19 pandemic the numbers of treated patients were reduced, especially in the first lockdown period (03/22/2020-05/05/2020 vs. same period in 2019: outpatient clinic (9 vs. 36; p < 0.001), patients surgically treated (27 vs. 52; p < 0,001)). The comparison of 2020 to 2019 showed a reduction in April 2020 of - 37% in outpatient department and up to - 90% for surgically treated patients. Comparing to 2019, we found a reduction of surgical interventions in 2020 by - 9% and an increase by 83% in 2021. CONCLUSIONS Raising numbers of patients treated for endometriosis point to a new awareness for the disease. After the decline during the lockdown period numbers raised again, leading to a delay, but not an omission of treatment. A certified endometriosis centre with established and well-organized structures is required to improve not only treatment results but also quality of life of those affected.
Collapse
Affiliation(s)
- Lucia Keilmann
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Susanne Beyer
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Sarah Meister
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Magdalena Jegen
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Christina Buschmann
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Lennard Schröder
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Simon Keckstein
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Udo Jeschke
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
- Department of Gynaecology and Obstetrics, University Hospital Augsburg, 86156, Augsburg, Germany.
| | - Alexander Burges
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Sven Mahner
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Fabian Trillsch
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Bernd Kost
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Thomas Kolben
- Department of Gynaecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| |
Collapse
|
16
|
Bazan J, Yaney A, Jhawar S, Beyer S, White J. Low Toxicity and Excellent Cosmesis with Highly Conformal Accelerated Partial Breast Irradiation Delivered Either Twice Daily or Every Other Day. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
17
|
Tong Z, Fleming J, Grozdic I, McElroy J, Beyer S, Fabian D, Becker A, Bell E, Mahler K, Popp I, Staszewski O, Manring H, Haque J, Grosu A, Chakravarti A. Therapeutic Potential of Small Molecule Inhibitors of TBK1 in Glioma. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Perlow H, Ho C, Matsui J, Prasad R, Klamer B, Wang J, Damante M, Blakaj D, Beyer S, Lonser R, Hardesty D, Raval R, Prabhu R, Elder J, Palmer J. Pre-Operative vs. Post-Operative Fractionated Stereotactic Radiotherapy for Patients with Brain Metastases: A Multi-Institutional Analysis. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Yaney A, Fort M, Jhawar S, Beyer S, White J, Bazan J. Prospective Evaluation of Implementation of Esophageal Dose-Volume Constraints in Patients with Breast Cancer Undergoing Regional Nodal Irradiation. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
20
|
Beyer S, Müller L, Mitter S, Keilmann L, Meister S, Buschmann C, Kraus F, Topalov NE, Czogalla B, Trillsch F, Burges A, Mahner S, Schmoeckel E, Löb S, Corradini S, Kessler M, Jeschke U, Kolben T. High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer. J Cancer Res Clin Oncol 2022:10.1007/s00432-022-04271-z. [PMID: 36068443 DOI: 10.1007/s00432-022-04271-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Accepted: 08/05/2022] [Indexed: 12/24/2022]
Abstract
PURPOSE Endometrial cancer is the most common gynecological malignancy. The helicase RIG-I, a part of the innate immune system, and EFTUD2, a splicing factor which can upregulate RIG-I expression, are shown to influence tumor growth and disease progression in several malignancies. For endometrial cancer, an immunogenic cancer, data about RIG-I and EFTUD2 are still missing. The aim of this study was to examine the expression of RIG-I and EFTUD2 in endometrial cancer. METHODS 225 specimen of endometrial cancer were immunohistochemically stained for RIG-I and EFTUD2. The results were correlated to clinicopathological data, overall survival (OS) and progression-free survival (PFS). RESULTS High RIG-I expression correlated with advanced tumor stages (FIGO: p = 0.027; pT: p = 0.010) and worse survival rates (OS: p = 0.009; PFS: p = 0.022). High EFTUD2 expression correlated to worse survival rates (OS: p = 0.026; PFS: p < 0.001) and was determined to be an independent marker for progression-free survival. CONCLUSION Our data suggest that the expression of RIG-I and EFTUD2 correlates with survival data, which makes both a possible therapeutic target in the future.
Collapse
Affiliation(s)
- Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Lena Müller
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Sophie Mitter
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Lucia Keilmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Sarah Meister
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Christina Buschmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Fabian Kraus
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Nicole E Topalov
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Bastian Czogalla
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Fabian Trillsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Alexander Burges
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Elisa Schmoeckel
- Institute of Pathology, University Hospital, LMU Munich, Munich, Germany
| | - Sanja Löb
- Department of Gynecology and Obstetrics, University Hospital Wuerzburg, Würzburg, Germany
| | - Stefanie Corradini
- Department of Radiation‑Oncology, University Hospital, LMU Munich, Munich, Germany
| | - Mirjana Kessler
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany. .,Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany.
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|
21
|
Kraus FBT, Topalov NE, Deuster E, Hysenaj I, Mayr D, Chelariu-Raicu A, Beyer S, Kolben T, Burges A, Mahner S, Trillsch F, Jeschke U, Czogalla B. Expression pattern and prognostic potential of histamine receptors in epithelial ovarian cancer. J Cancer Res Clin Oncol 2022; 149:2501-2511. [PMID: 35751684 PMCID: PMC10129941 DOI: 10.1007/s00432-022-04114-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Accepted: 06/06/2022] [Indexed: 10/17/2022]
Abstract
PURPOSE Despite recent advances in the treatment of ovarian cancer (OC), long-term remissions remain scarce. For a targeted approach, prognostic markers are indispensable for predicting survival and treatment response. Given their association with multiple hallmarks of cancer, histamine receptors (HR) are emerging as promising candidates. Here, we investigate their expression pattern and prognostic value in OC. METHODS Specimens of 156 epithelial OC patients were collected during cytoreductive surgery at the Department of Obstetrics and Gynecology, LMU, between 1990 and 2002 and combined in a tissue microarray. Immunohistochemical staining of the HR H1, H2, H3 and H4 was quantified by an immunoreactive score and linked with clinico-pathological data by Spearman's correlation. Via ROC curve analysis, optimal cut-off values for potential prognostic markers were defined. Overall survival (OS) was visualized in Kaplan-Maier curves and significances determined by log-rank testing. A Cox regression model was applied for multivariate analysis. RESULTS HR H3 and H4 expression was restricted to the cytosol of OC cells, while H1 was also present in the nucleus. A significant association between HR H1, H3 and H4 expression with several clinico-pathological parameters was revealed. In addition, HR H1 and H3 expression correlated positively, HR H4 expression negatively with OS. In addition, HR H3 was identified as independent prognostic marker for OS. HR H2 expression had no prognostic value. CONCLUSIONS HR H1, H3 and H4 could serve as potential predictors for OS of OC patients. Further research is warranted to elucidate their pathophysiologic role and their predictive and therapeutic potential in OC.
Collapse
Affiliation(s)
- Fabian B T Kraus
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.
| | - Nicole E Topalov
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - E Deuster
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - I Hysenaj
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - D Mayr
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - A Chelariu-Raicu
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - S Beyer
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - T Kolben
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - A Burges
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - S Mahner
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - F Trillsch
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| | - U Jeschke
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany.,Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany
| | - B Czogalla
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|
22
|
Hahn L, Meister S, Mannewitz M, Beyer S, Corradini S, Hasbargen U, Mahner S, Jeschke U, Kolben T, Burges A. Gal-2 Increases H3K4me3 and H3K9ac in Trophoblasts and Preeclampsia. Biomolecules 2022; 12:biom12050707. [PMID: 35625634 PMCID: PMC9139023 DOI: 10.3390/biom12050707] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2022] [Revised: 05/11/2022] [Accepted: 05/13/2022] [Indexed: 12/10/2022] Open
Abstract
Preeclampsia (PE) is a severe pregnancy disorder with a pathophysiology not yet completely understood and without curative therapy. The histone modifications H3K4me3 and H3K9ac, as well as galectin-2 (Gal-2), are known to be decreased in PE. To gain a better understanding of the development of PE, the influence of Gal-2 on histone modification in trophoblasts and in syncytialisation was investigated. Immunohistochemical stains of 13 PE and 13 control placentas were correlated, followed by cell culture experiments. An analysis of H3K4me3 and H3K9ac was conducted, as well as cell fusion staining with E-cadherin and β-catenin—both after incubation with Gal-2. The expression of H3K4me3 and H3K9ac correlated significantly with the expression of Gal-2. Furthermore, we detected an increase in H3K4me3 and H3K9ac after the addition of Gal-2 to BeWo/HVT cells. Moreover, there was increased fusion of HVT cells after incubation with Gal-2. Gal-2 is associated with the histone modifications H3K4me3 and H3K9ac in trophoblasts. Furthermore, syncytialisation increased after incubation with Gal-2. Therefore, we postulate that Gal-2 stimulates syncytialisation, possibly mediated by H3K4me3 and H3K9ac. Since Gal-2, as well as H3K4me3 and H3K9ac, are decreased in PE, the induction of Gal-2 might be a promising therapeutic target.
Collapse
Affiliation(s)
- Laura Hahn
- Department of Obsterics and Gynecology, University Hospital, Ludwig-Maximilians-Universität Munich, Marchioninistr. 15, 81337 Munich, Germany; (S.M.); (M.M.); (S.B.); (U.H.); (S.M.); (U.J.); (T.K.); (A.B.)
- Correspondence: ; Tel.: +49-89-440073800
| | - Sarah Meister
- Department of Obsterics and Gynecology, University Hospital, Ludwig-Maximilians-Universität Munich, Marchioninistr. 15, 81337 Munich, Germany; (S.M.); (M.M.); (S.B.); (U.H.); (S.M.); (U.J.); (T.K.); (A.B.)
| | - Mareike Mannewitz
- Department of Obsterics and Gynecology, University Hospital, Ludwig-Maximilians-Universität Munich, Marchioninistr. 15, 81337 Munich, Germany; (S.M.); (M.M.); (S.B.); (U.H.); (S.M.); (U.J.); (T.K.); (A.B.)
| | - Susanne Beyer
- Department of Obsterics and Gynecology, University Hospital, Ludwig-Maximilians-Universität Munich, Marchioninistr. 15, 81337 Munich, Germany; (S.M.); (M.M.); (S.B.); (U.H.); (S.M.); (U.J.); (T.K.); (A.B.)
| | - Stefanie Corradini
- Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-Universität Munich, Marchioninistr. 15, 81337 Munich, Germany;
| | - Uwe Hasbargen
- Department of Obsterics and Gynecology, University Hospital, Ludwig-Maximilians-Universität Munich, Marchioninistr. 15, 81337 Munich, Germany; (S.M.); (M.M.); (S.B.); (U.H.); (S.M.); (U.J.); (T.K.); (A.B.)
| | - Sven Mahner
- Department of Obsterics and Gynecology, University Hospital, Ludwig-Maximilians-Universität Munich, Marchioninistr. 15, 81337 Munich, Germany; (S.M.); (M.M.); (S.B.); (U.H.); (S.M.); (U.J.); (T.K.); (A.B.)
| | - Udo Jeschke
- Department of Obsterics and Gynecology, University Hospital, Ludwig-Maximilians-Universität Munich, Marchioninistr. 15, 81337 Munich, Germany; (S.M.); (M.M.); (S.B.); (U.H.); (S.M.); (U.J.); (T.K.); (A.B.)
- Department of Gynecology and Obsterics, University Hospital Augsburg, 86156 Augsburg, Germany
| | - Thomas Kolben
- Department of Obsterics and Gynecology, University Hospital, Ludwig-Maximilians-Universität Munich, Marchioninistr. 15, 81337 Munich, Germany; (S.M.); (M.M.); (S.B.); (U.H.); (S.M.); (U.J.); (T.K.); (A.B.)
| | - Alexander Burges
- Department of Obsterics and Gynecology, University Hospital, Ludwig-Maximilians-Universität Munich, Marchioninistr. 15, 81337 Munich, Germany; (S.M.); (M.M.); (S.B.); (U.H.); (S.M.); (U.J.); (T.K.); (A.B.)
| |
Collapse
|
23
|
Hahn L, Meister S, Mannewitz M, Beyer S, Corradini S, Hasbargen U, Mahner S, Jeschke U, Kolben T, Burges A. Gal-2 führt zu einer Erhöhung von H3K4me3 und H3K9ac
in Trophoblasten und in der Präeklampsie. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- L Hahn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - M Mannewitz
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie,
Klinikum der LMU München
| | - U Hasbargen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
- Klinik für Frauenheilkunde und Geburtshilfe,
Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der LMU München
| |
Collapse
|
24
|
Müller L, Mitter S, Mannewitz M, Keilmann L, Meister S, Kolben MT, Schmoeckel E, Burges A, Trillsch F, Czogalla B, Jeschke U, Kessler M, Mahner S, Kolben T, Beyer S. Die Blutgruppenantigene SLeX, SLeA and Lewis Y als potenziell prognostische Faktoren im Endometrium- und Zervixkarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Affiliation(s)
- L Müller
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mitter
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Mannewitz
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - L Keilmann
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Meister
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - E Schmoeckel
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - A Burges
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - F Trillsch
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - B Czogalla
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - U Jeschke
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - M Kessler
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Beyer
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| |
Collapse
|
25
|
Topalov EN, Mayr D, Scherer C, Chelariu-Raicu A, Beyer S, Hester A, Kraus FBT, Zheng M, Kaltofen T, Kolben T, Burges A, Mahner S, Trillsch F, Jeschke U, Czogalla B. Die funktionelle Rolle von Actin beta-like 2 in der Pathogenese des Ovarialkarzinoms und dessen prognostische Bedeutung für das Gesamtüberleben. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- E N Topalov
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - D Mayr
- Pathologisches Institut, Medizinische Fakultät, Universitätsklinikum der LMU, München
| | - C Scherer
- Medizinische Klinik und Poliklinik I, Universitätsklinikum der LMU, München
- DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung e.V.), Munich Heart Alliance, Universitätsklinikum der LMU, München
| | - A Chelariu-Raicu
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - FBT Kraus
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Zheng
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - T Kaltofen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| |
Collapse
|
26
|
Dreyer EM, Meister S, Thomann M, Hahn L, Keilmann L, Beyer S, Mayer C, Prins G, Hermelink K, Hasbargen U, Mahner S, Kolben T. Einfluss der psychischen Belastung durch die COVID-19-Pandemie auf
das Auftreten von Wochenbettdepressionen und die Relevanz individueller
Stressbewältigungs-Strategien. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- E-M Dreyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - M Thomann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - L Hahn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - L Keilmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - C Mayer
- Fakultät für Psychologie, Universität
Würzburg
| | - G Prins
- Fakultät für Sozialwissenschaften, Universität
Augsburg
| | - K Hermelink
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - U Hasbargen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe,
Klinikum der Universität München, LMU
München
| |
Collapse
|
27
|
Mitter S, Müller L, Mannewitz M, Keilmann L, Meister S, Kolben MT, Schmoeckel E, Burges A, Trillsch F, Czogalla B, Mahner S, Kessler M, Jeschke U, Kolben T, Beyer S. RIG-I – Expression als negativer prognostischer Faktor im Endometriumkarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- S Mitter
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - L Müller
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Mannewitz
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - L Keilmann
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Meister
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - E Schmoeckel
- Pathologisches Institut, Universitätsklinikum der LMU, München
| | - A Burges
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - F Trillsch
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - B Czogalla
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Kessler
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - U Jeschke
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - T Kolben
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Beyer
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| |
Collapse
|
28
|
Kraus FBT, Topalov EN, Deuster E, Hysenaj I, Mayr D, Chelariu-Raicu A, Beyer S, Kolben T, Burges A, Mahner S, Trillsch F, Jeschke U, Czogalla B. Expressionsmuster und prädiktives Potenzial der Histaminrezeptoren im Ovarialkarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- FBT Kraus
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - E N Topalov
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - E Deuster
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - I Hysenaj
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - D Mayr
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - A Chelariu-Raicu
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| |
Collapse
|
29
|
Bedford E, Russo V, Dickman C, Li B, Jezierski A, Kim D, Jang J, Yin Y, Harrington D, Sharma R, De la Vega L, Willerth S, Salmeron L, Morgan J, Kieffer T, Beyer S, Mohamed T, Witek R, Getsios S, Wadsworth S. Tissue Engineering, Embryonic, Organ and Other Tissue Specific Stem Cells: PARTNERING TO ADVANCE THE DEVELOPMENT OF TISSUE THERAPEUTICS WITH MICROFLUIDIC 3D BIOPRINTING. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00412-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
30
|
Beyer S, Wehrmann M, Meister S, Kolben TM, Trillsch F, Burges A, Czogalla B, Schmoeckel E, Mahner S, Jeschke U, Kolben T. Galectin-8 and -9 as prognostic factors for cervical cancer. Arch Gynecol Obstet 2022; 306:1211-1220. [PMID: 35377045 PMCID: PMC9470666 DOI: 10.1007/s00404-022-06449-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2020] [Accepted: 02/09/2022] [Indexed: 11/21/2022]
Abstract
Purpose Galectins are carbohydrate-binding proteins with multiple effects on cell biology. Research shows that they play an important role in tumor development and progression. Therefore, in this study, the presence of Galectin-8 and -9 (Gal), both already known as prognostic factors in other tumor entities, were investigated in cervical cancer. Our aim was to examine the association of Gal-8 and -9 expression with histopathological markers and survival of the patients. Methods Gal-8 and -9 expression was investigated in 250 cervical cancer samples by immunohistochemistry. The staining was evaluated using the immunoreactive score (IRS). The results were correlated to clinical and pathological data. The correlation of Gal-8 and -9 expression with overall and relapse-free survival was analyzed. Results Expression of Gal-8 was associated with negative N-status and lower FIGO status. Detection of Gal-9 was connected to negative N-status and lower grading regarding all specimens. A correlation of Gal-9 with lower FIGO status was detected for squamous cell carcinoma (SCC) only. Expression of Gal-8 was associated with relapse-free survival of SCC patients in a positive manner. Gal-9 expression was associated with better overall survival. Conclusion Our results suggest that expression of both galectins is inversely associated with tumor stage and progression. Gal-8 expression is associated with relapse-free survival of patients with SCC, while presence of Gal-9 in cervical cancer is associated with a better prognosis in regard of overall survival. Supplementary Information The online version contains supplementary material available at 10.1007/s00404-022-06449-9.
Collapse
Affiliation(s)
- Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Maya Wehrmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Sarah Meister
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Theresa M Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Fabian Trillsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Alexander Burges
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Bastian Czogalla
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Elisa Schmoeckel
- Institute of Pathology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.,Department of Obstetrics and Gynecology, University Hospital, Universitätsklinikum Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| |
Collapse
|
31
|
Badmann S, Mayr D, Schmoeckel E, Hester A, Buschmann C, Beyer S, Kolben T, Kraus F, Chelariu-Raicu A, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B. AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin. Sci Rep 2022; 12:1862. [PMID: 35115586 PMCID: PMC8814148 DOI: 10.1038/s41598-022-05785-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Accepted: 01/18/2022] [Indexed: 11/25/2022] Open
Abstract
In recurrent epithelial ovarian cancer (EOC) most patients develop platinum-resistance. On molecular level the NRF2 pathway, a cellular defense mechanism against reactive oxygen species, is induced. In this study, we investigate AKR1C1/2, target of NRF2, in a well-established EOC collective by immunohistochemistry and in a panel of ovarian cancer cell lines including platinum-resistant clones. The therapeutic effect of carboplatin and MPA as monotherapy or in combination was assessed by functional assays, using OV90 and OV90cp cells. Molecular mechanisms of action of MPA were investigated by NRF2 silencing and AKR activity measurements. Immunohistochemical analysis revealed that AKR1C1/2 is a key player in the development of chemoresistance and an independent indicator for short PFS (23.5 vs. 49.6 months, p = 0.013). Inhibition of AKR1C1/2 by MPA led to a concentration- and time-dependent decline of OV90 viability and to an increased response to CP in vitro. By NRF2 silencing, however, the effects of MPA treatment were reduced. Concludingly, our data suggest that a combination therapy of carboplatin and MPA might be a promising therapeutic approach to increase response rates of EOC patients, which should be explored in clinical context.
Collapse
Affiliation(s)
- Susann Badmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany
| | - Doris Mayr
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Elisa Schmoeckel
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Anna Hester
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany
| | - Christina Buschmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany
| | - Fabian Kraus
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany
| | - Anca Chelariu-Raicu
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany
| | - Alexander Burges
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany.,Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany
| | - Fabian Trillsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany
| | - Bastian Czogalla
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany.
| |
Collapse
|
32
|
Meister S, Kellner I, Beyer S, Corradini S, Schulz C, Rogenhofer N, Keilmann L, Kolben TM, Mahner S, Kessler M, Jeschke U, Kolben T. Epigenetic changes occur in placentas of spontaneous and recurrent miscarriages. J Reprod Immunol 2021; 149:103466. [PMID: 34929495 DOI: 10.1016/j.jri.2021.103466] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 10/18/2021] [Accepted: 12/12/2021] [Indexed: 12/21/2022]
Abstract
BACKGROUND In contrast to genetic abnormalities which are well known to be responsible for around 50 % of human miscarriages, there is very few data about epigenetic alterations in spontaneous and recurrent miscarriages (SM, RM). The aim of this study was to analyze the histone modification marks H3K9ac and H3K4me3 in SM and RM. METHODS The abundance of histone modifications H3K4me3/H3K9ac was analyzed by western blot in frozen abortion material of SM and RM compared to a control group of legal pregnancy terminations. Further, to characterize placental tissue cells expressing H3K4me3/H3K9ac immunohistochemistry (IHC) and immunofluorescence was performed in 20 SM, 19 RM and 26 controls. RESULTS The western blot data showed a tendency to an overall reduction of H3K4me3/H3K9ac, in the placental tissue of particularly SM. Further we differentiated between syncytiotrophoblast, cytotrophoblast and decidual cells and found a significant decrease of H3K4me3 in SM in cytotrophoblast cells and syncytial stroma. In RM H3K4me3 was downregulated exclusively in the syncytiotrophoblast. H3K9ac was reduced in SM and RM in all evaluated compartments, except from the syncytiotrophoblast. CONCLUSION Our study showed an overall reduced histone modification of H3K4me3 and H3K9ac in the placental tissue of SM. Concerning RM, particularly the reduction of H3K9ac was detected in the placental tissue, indicating that RM group has distinct profile in epigenetic regulation. Whether these histone modifications are part of a possible pathophysiologic cascade during SM and RM or are merely indicating a defective placentation, cannot be concluded from this study.
Collapse
Affiliation(s)
- Sarah Meister
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany; Walter-Brendel-Centre of Experimental Medicine, University Hospital, LMU Munich, Munich, Germany.
| | - Isabel Kellner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Stefanie Corradini
- Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Germany
| | - Christian Schulz
- Medizinische Klinik und Poliklinik I, Klinikum der Universität, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany
| | - Nina Rogenhofer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Lucia Keilmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Theresa Maria Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Mirjana Kessler
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany; Department of Gynecology and Obstetrics, University Hospital Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| |
Collapse
|
33
|
Meister S, Hahn L, Beyer S, Paul C, Mitter S, Kuhn C, von Schönfeldt V, Corradini S, Sudan K, Schulz C, Kolben TM, Mahner S, Jeschke U, Kolben T. Regulation of Epigenetic Modifications in the Placenta during Preeclampsia: PPARγ Influences H3K4me3 and H3K9ac in Extravillous Trophoblast Cells. Int J Mol Sci 2021; 22:ijms222212469. [PMID: 34830351 PMCID: PMC8622744 DOI: 10.3390/ijms222212469] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 11/15/2021] [Accepted: 11/15/2021] [Indexed: 12/12/2022] Open
Abstract
The aim of this study was to analyze the expression of peroxisome proliferator-activated receptor γ (PPARγ) and retinoid X receptor α (RxRα), a binding heterodimer playing a pivotal role in the successful trophoblast invasion, in the placental tissue of preeclamptic patients. Furthermore, we aimed to characterize a possible interaction between PPARγ and H3K4me3 (trimethylated lysine 4 of the histone H3), respectively H3K9ac (acetylated lysine 9 of the histone H3), to illuminate the role of histone modifications in a defective trophoblast invasion in preeclampsia (PE). Therefore, the expression of PPARγ and RxRα was analyzed in 26 PE and 25 control placentas by immunohistochemical peroxidase staining, as well as the co-expression with H3K4me3 and H3K9ac by double immunofluorescence staining. Further, the effect of a specific PPARγ-agonist (Ciglitazone) and PPARγ-antagonist (T0070907) on the histone modifications H3K9ac and H3K4me3 was analyzed in vitro. In PE placentas, we found a reduced expression of PPARγ and RxRα and a reduced co-expression with H3K4me3 and H3K9ac in the extravillous trophoblast (EVT). Furthermore, with the PPARγ-antagonist treated human villous trophoblast (HVT) cells and primary isolated EVT cells showed higher levels of the histone modification proteins whereas treatment with the PPARγ-agonist reduced respective histone modifications. Our results show that the stimulation of PPARγ-activity leads to a reduction of H3K4me3 and H3K9ac in trophoblast cells, but paradoxically decreases the nuclear PPARγ expression. As the importance of PPARγ, being involved in a successful trophoblast invasion has already been investigated, our results reveal a pathophysiologic connection between PPARγ and the epigenetic modulation via H3K4me3 and H3K9ac in PE.
Collapse
Affiliation(s)
- Sarah Meister
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; (L.H.); (S.B.); (C.P.); (S.M.); (V.v.S.); (T.M.K.); (S.M.); (T.K.)
- Correspondence: (S.M.); (U.J.); Tel.: +49-89-4400-54266 (S.M.); Fax: +49-89-4400-54916 (S.M.)
| | - Laura Hahn
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; (L.H.); (S.B.); (C.P.); (S.M.); (V.v.S.); (T.M.K.); (S.M.); (T.K.)
| | - Susanne Beyer
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; (L.H.); (S.B.); (C.P.); (S.M.); (V.v.S.); (T.M.K.); (S.M.); (T.K.)
| | - Corinna Paul
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; (L.H.); (S.B.); (C.P.); (S.M.); (V.v.S.); (T.M.K.); (S.M.); (T.K.)
| | - Sophie Mitter
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; (L.H.); (S.B.); (C.P.); (S.M.); (V.v.S.); (T.M.K.); (S.M.); (T.K.)
| | - Christina Kuhn
- Department of Gynecology and Obstetrics, University Hospital Augsburg, 86156 Augsburg, Germany;
| | - Viktoria von Schönfeldt
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; (L.H.); (S.B.); (C.P.); (S.M.); (V.v.S.); (T.M.K.); (S.M.); (T.K.)
| | - Stefanie Corradini
- Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany;
| | - Kritika Sudan
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; (K.S.); (C.S.)
| | - Christian Schulz
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; (K.S.); (C.S.)
| | - Theresa Maria Kolben
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; (L.H.); (S.B.); (C.P.); (S.M.); (V.v.S.); (T.M.K.); (S.M.); (T.K.)
| | - Sven Mahner
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; (L.H.); (S.B.); (C.P.); (S.M.); (V.v.S.); (T.M.K.); (S.M.); (T.K.)
| | - Udo Jeschke
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; (L.H.); (S.B.); (C.P.); (S.M.); (V.v.S.); (T.M.K.); (S.M.); (T.K.)
- Department of Gynecology and Obstetrics, University Hospital Augsburg, 86156 Augsburg, Germany;
- Correspondence: (S.M.); (U.J.); Tel.: +49-89-4400-54266 (S.M.); Fax: +49-89-4400-54916 (S.M.)
| | - Thomas Kolben
- Department of Gynecology and Obstetrics, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany; (L.H.); (S.B.); (C.P.); (S.M.); (V.v.S.); (T.M.K.); (S.M.); (T.K.)
| |
Collapse
|
34
|
Raj R, Jhawar S, Stover D, Park K, Beyer S, Healy E, White J, Bazan J. De-Escalation of Radiation Therapy in Patients with cT1-T2 (< 3 cm) N0 HER2+ Breast Cancer Treated With Neoadjuvant Systemic Therapy With Pathologic Complete Response at the Time of Breast Conserving Surgery. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Dibs K, Palmer J, Olausson A, Bourekas E, Boulter D, Ayan A, Cochran E, Yildiz V, Grecula J, Arnett A, Raval R, Beyer S, Scharschmidt T, Elder J, Chakravarti A, Mendel E, Blakaj D. Circumferential Stereotactic Body Radiotherapy for Spine Metastasis: The Feasibility, Toxicity and Local Control. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1619] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Mladkova N, Smith T, Yildiz V, Healy E, Beyer S, DiCostanzo D, Jhawar S, Bazan J, White J. The Impact of Bioabsorbable 3D Fiducial Marker on Radiation Dosimetry and Cosmesis in Early Stage Breast Cancer. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
37
|
Hatton C, Bailey T, Bradshaw J, Caton S, Flynn S, Gillooly A, Jahoda A, Maguire R, Marriott A, Mulhall P, Oloidi E, Taggart L, Todd S, Abbott D, Beyer S, Gore N, Heslop P, Scior K, Hastings RP. The willingness of UK adults with intellectual disabilities to take COVID-19 vaccines. J Intellect Disabil Res 2021; 65:949-961. [PMID: 34529314 PMCID: PMC8657332 DOI: 10.1111/jir.12884] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Revised: 07/29/2021] [Accepted: 08/29/2021] [Indexed: 06/13/2023]
Abstract
BACKGROUND Given the much greater COVID-19 mortality risk experienced by people with intellectual disabilities (ID), understanding the willingness of people with ID to take a COVID-19 vaccine is a major public health issue. METHOD In December 2020 to February 2021, across the United Kingdom, 621 adults with ID were interviewed remotely and 348 family carers or support workers of adults with ID with greater needs completed an online survey, including a question on willingness to take a COVID-19 vaccine if offered. RESULTS Eighty-seven per cent of interviewees with ID were willing to take a COVID-19 vaccine, with willingness associated with white ethnicity, having already had a flu vaccine, gaining information about COVID-19 from television but not from social media, and knowing COVID-19 social restrictions rules. A percentage of 81.7% of surveyed carers of adults with ID with greater needs reported that the person would be willing to take a COVID-19 vaccine, with willingness associated with white ethnicity, having a health condition of concern in the context of COVID-19, having had a flu vaccine, being close to someone who had died due to COVID-19, and having shielded at some point during the pandemic. CONCLUSIONS Reported willingness to take the COVID-19 vaccine is high among adults with ID in the United Kingdom, with factors associated with willingness having clear implications for public health policy and practice.
Collapse
Affiliation(s)
- C. Hatton
- Department of Social Care and Social WorkManchester Metropolitan UniversityManchesterUK
| | - T. Bailey
- Centre for Educational Development, Appraisal and ResearchUniversity of WarwickCoventryUK
| | | | - S. Caton
- Department of Social Care and Social WorkManchester Metropolitan UniversityManchesterUK
| | - S. Flynn
- Centre for Educational Development, Appraisal and ResearchUniversity of WarwickCoventryUK
| | - A. Gillooly
- Institute of Health and WellbeingUniversity of GlasgowGlasgowUK
| | - A. Jahoda
- Institute of Health and WellbeingUniversity of GlasgowGlasgowUK
| | - R. Maguire
- Institute of Health and WellbeingUniversity of GlasgowGlasgowUK
| | - A. Marriott
- National Development Team for InclusionBathUK
| | - P. Mulhall
- Institute of Nursing and Health ResearchUniversity of UlsterJordanstownUK
| | - E. Oloidi
- Unit for Development in Intellectual and Developmental DisabilitiesUniversity of South WalesPontypriddUK
| | - L. Taggart
- Institute of Nursing and Health ResearchUniversity of UlsterJordanstownUK
| | - S. Todd
- Unit for Development in Intellectual and Developmental DisabilitiesUniversity of South WalesPontypriddUK
| | - D. Abbott
- School for Policy StudiesUniversity of BristolBristolUK
| | - S. Beyer
- School of MedicineUniversity of CardiffCardiffUK
| | - N. Gore
- Tizard CentreUniversity of KentCanterburyUK
| | - P. Heslop
- School for Policy StudiesUniversity of BristolBristolUK
| | - K. Scior
- Division of Psychology and Language SciencesUniversity College LondonLondonUK
| | - R. P. Hastings
- Centre for Educational Development, Appraisal and ResearchUniversity of WarwickCoventryUK
- Centre for Developmental Psychiatry and PsychologyMonash UniversityMelbourneVICAustralia
| |
Collapse
|
38
|
Kumar A, Rajasekera P, Biehn S, Beyer S, McElroy J, Becker A, Johnson B, Cui T, Sebastian E, Grosu A, Lindert S, Bell E, Haque S, Chakravarti A. In-Silico Discovery of Novel Small-Molecule Inhibitors Targeting Transgelin-2-Actin Interaction Inhibits Proliferation, Invasion and Improves Chemo-Radiation Response in Human Glioblastoma. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
39
|
Perlow H, Yang M, Siedow M, Boulter D, Fritz J, Miller E, Blakaj D, Zoller W, Cadieux C, Eiler D, Addington M, DiCostanzo D, Beyer S, Arnett A, Grecula J, Chakravarti A, Palmer J. 68(GA)DOTATATE PET-Based Radiation Volumes Demonstrate Increased Precision Compared to MRI Based Volumes for Meningioma Patients. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
Forster M, Wuerstlein R, Koenig A, Amann N, Beyer S, Kaltofen T, Degenhardt T, Burges A, Trillsch F, Mahner S, Harbeck N, Chelariu-Raicu A. COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective. Breast 2021; 60:214-222. [PMID: 34736092 PMCID: PMC8555340 DOI: 10.1016/j.breast.2021.10.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2021] [Revised: 10/26/2021] [Accepted: 10/29/2021] [Indexed: 01/22/2023] Open
Abstract
INTRODUCTION The side effects of systemic cancer therapy and the lack of clinical data on safety and efficacy of COVID-19 vaccination in cancer patients cause uncertainty among the patients about whether to get vaccinated or not. Here, we evaluated attitude towards and effects of COVID-19 vaccination in patients with breast and gynecological cancer undergoing systemic cancer therapy. METHODS Since March 15th, 2021, cancer patients who received one of the approved COVID-19 vaccines were routinely interviewed about immediate and late side effects. Clinical parameters such as current therapy, time interval between therapy administration and vaccination, and changes in the therapy schedule due to vaccination were documented. The collected data were analyzed de-identified as a part of routine quality assurance. RESULTS By July 27th, 2021, 218 patients (74.3% breast cancer patients) had received one of two COVID-19 vaccine doses, and 112 patients had received both doses: 77.5% received Conmirnaty (BioNTech/Pfizer), 16.1% Vaxzevria (Astra Zeneca) and 5.9% COVID-19 Vaccine Moderna. The COVID-19 vaccines had an acceptable safety profile with self-limiting local and systemic adverse events, which rarely lasted >48 h post vaccination. Symptoms occurred predominantly after the second dose of the vaccine and less frequently in older patients >55 years. No vaccine-related serious adverse events were reported, and only limited effects of vaccination on the therapy schedule were observed. CONCLUSIONS Breast and gynecologic cancer patients tolerate the COVID-19 vaccination while undergoing systemic cancer therapy without any additional side effects beyond those reported in the general population.
Collapse
Affiliation(s)
- Marie Forster
- Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany
| | - Rachel Wuerstlein
- Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany
| | - Alexander Koenig
- Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany
| | - Niklas Amann
- Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany
| | - Till Kaltofen
- Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany
| | - Tom Degenhardt
- Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany
| | - Alexander Burges
- Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany
| | - Fabian Trillsch
- Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany
| | - Nadia Harbeck
- Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany
| | - Anca Chelariu-Raicu
- Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany.
| |
Collapse
|
41
|
Topalov NE, Mayr D, Scherer C, Chelariu-Raicu A, Beyer S, Hester A, Kraus F, Zheng M, Kaltofen T, Kolben T, Burges A, Mahner S, Trillsch F, Jeschke U, Czogalla B. Actin Beta-Like 2 as a New Mediator of Proliferation and Migration in Epithelial Ovarian Cancer. Front Oncol 2021; 11:713026. [PMID: 34631538 PMCID: PMC8495414 DOI: 10.3389/fonc.2021.713026] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Accepted: 08/25/2021] [Indexed: 11/16/2022] Open
Abstract
The impact of Actin beta-like 2 (ACTBL2), a novel described actin isoform, on epithelial ovarian cancer (EOC) biology has not been investigated so far. In this study, we analyzed the prognostic and functional significance of ACTBL2 and its regulatory element Nuclear factor of activated T-cells 5 (NFAT5). The expression of ACTBL2 and NFAT5 was examined in tissue microarrays of 156 ovarian cancer patients by immunohistochemistry. Aiming to assess the molecular impact of ACTBL2 on cellular characteristics, functional assays were executed in vitro upon siRNA knockdown of ACTBL2 and NFAT5. ACTBL2 expression was identified as an independent negative prognostic factor for overall survival of EOC patients. EOC cell lines showed a significantly increased mRNA and protein level of ACTBL2 compared to the benign control. In vitro analyses upon siRNA knockdown of ACTBL2 displayed a significantly reduced cellular viability, proliferation and migration. siRNA knockdown of NFAT5 proved a significant molecular interplay by inducing a downregulation of ACTBL2 with a thus resulting concordant alteration in cellular functions, predominantly reflected in a decreased migratory potential of EOC cells. Our results provide significant evidence on the negative prognostic impact of ACTBL2 in EOC, suggesting its crucial importance in ovarian carcinogenesis by modulating cellular motility and proliferation.
Collapse
Affiliation(s)
| | - Doris Mayr
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Clemens Scherer
- Department of Medicine I, University Hospital, LMU Munich, Munich, Germany.,5DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, University Hospital, LMU Munich, Munich, Germany
| | - Anca Chelariu-Raicu
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Anna Hester
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Fabian Kraus
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Mingjun Zheng
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Till Kaltofen
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Alexander Burges
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Fabian Trillsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.,Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany
| | - Bastian Czogalla
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|
42
|
Kolben T, Beyer S, Ghasemi S, Hermelink K, Meister S, Degenhardt T, Himsl I, Edler von Koch F, Kolben TM, Wuerstlein R, Mahner S, Harbeck N, Hester A. Late Presentation at Primary Diagnosis of Breast Cancer: Patients' Personality Characteristics and Attitudes. Breast Care (Basel) 2021; 16:343-349. [PMID: 34602939 DOI: 10.1159/000509597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Accepted: 06/23/2020] [Indexed: 11/19/2022] Open
Abstract
Introduction Breast cancer (BC) is the most common cancer in women worldwide. Despite screening and information efforts, about 10% of patients present with tumor size T3 or T4 at primary diagnosis. Late presentation is associated with more advanced tumor stage and consecutively with worse survival rates. Objective This study aimed to evaluate whether patients with a late presentation at primary BC diagnosis differ in their personality from those with early diagnosis. Methods In this bicentric, observational study, personality traits, positive and negative affectivity, anxiety, spirituality, illness beliefs, and sociodemographic characteristics were assessed in BC patients who presented with T-stages 3 or 4 (late presenters) and T-stages 1 or 2 (controls) at initial diagnosis. Results Forty patients (20 controls, 20 late presenters) were interviewed. "Late presenters" perceived their disease as long lasting and had significantly more "positive affectivity" in the current trait. Although no significant associations were found, there was a trend for late presenters to have higher education levels, less spiritual longing, less accurate explanation of their illness, less anxiety in the trait scale, and more conscientiousness than the controls. Conclusion As patients with late presentation for BC differ in specific psychological and sociodemographic characteristics from patients with early BC, the findings of this pilot project warrant additional investigations to identify further specific characteristics and motivations. Identifying patients at risk for late presentation and encouraging them to accept an earlier diagnosis could help to improve their therapy and, finally, their outcome.
Collapse
Affiliation(s)
- Thomas Kolben
- Department of Obstetrics and Gynecology, Breast Center and CCC LMU University Hospital, LMU Munich, Munich, Germany
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, Breast Center and CCC LMU University Hospital, LMU Munich, Munich, Germany
| | - Sanaz Ghasemi
- Department of Obstetrics and Gynecology, Breast Center and CCC LMU University Hospital, LMU Munich, Munich, Germany
| | - Kerstin Hermelink
- Department of Obstetrics and Gynecology, Breast Center and CCC LMU University Hospital, LMU Munich, Munich, Germany
| | - Sarah Meister
- Department of Obstetrics and Gynecology, Breast Center and CCC LMU University Hospital, LMU Munich, Munich, Germany
| | - Tom Degenhardt
- Department of Obstetrics and Gynecology, Breast Center and CCC LMU University Hospital, LMU Munich, Munich, Germany
| | - Isabelle Himsl
- Department of Obstetrics and Gynecology, Klinikum Dritter Orden, Munich, Germany
| | - Franz Edler von Koch
- Department of Obstetrics and Gynecology, Klinikum Dritter Orden, Munich, Germany
| | - Theresa M Kolben
- Department of Obstetrics and Gynecology, Breast Center and CCC LMU University Hospital, LMU Munich, Munich, Germany
| | - Rachel Wuerstlein
- Department of Obstetrics and Gynecology, Breast Center and CCC LMU University Hospital, LMU Munich, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, Breast Center and CCC LMU University Hospital, LMU Munich, Munich, Germany
| | - Nadia Harbeck
- Department of Obstetrics and Gynecology, Breast Center and CCC LMU University Hospital, LMU Munich, Munich, Germany
| | - Anna Hester
- Department of Obstetrics and Gynecology, Breast Center and CCC LMU University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|
43
|
Karsten N, Kolben T, Mahner S, Beyer S, Meister S, Kuhn C, Schmoeckel E, Wuerstlein R, Harbeck N, Ditsch N, Jeschke U, Friese K, Kolben TM. The role of E-Cadherin expression in primary site of breast cancer. Arch Gynecol Obstet 2021; 305:913-920. [PMID: 34510244 PMCID: PMC8967771 DOI: 10.1007/s00404-021-06198-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Accepted: 08/17/2021] [Indexed: 12/15/2022]
Abstract
PURPOSE The tumour's ability to metastasize is the major cause for fatal outcomes in cancer diseases. In breast cancer, aberrant E-Cadherin expression has been linked to invasiveness and poor prognosis. METHOD We assessed expression of E-Cadherin by immunohistochemistry in primary tumour tissue from 125 female breast cancer patients. Staining intensities were analysed using the immunoreactive score (IRS). We investigated E-Cadherin expression and its associations with clinicopathological parameters (age, tumour size, lymph node status, grade, hormone receptors, Her2 Status) as well as with recurrence and survival. RESULTS Increased, rather than aberrant E-Cadherin expression was found and was associated with poor outcome (p = 0.046). Our data show an association between elevated E-Cadherin in primary tumour tissue and an unfavourable negative prognosis in patients. CONCLUSION This association was somehow unexpected as loss of E-Cadherin has long been regarded as a prerequisite for development of invasiveness and metastases. Our findings support the notion that E-Cadherin promotes, rather than suppresses, development of metastasis and invasiveness.
Collapse
Affiliation(s)
- Nora Karsten
- Department of Obstetrics and Gynaecology, Breast Center and CCCLMU, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynaecology, Breast Center and CCCLMU, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynaecology, Breast Center and CCCLMU, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany
| | - Susanne Beyer
- Department of Obstetrics and Gynaecology, Breast Center and CCCLMU, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany
| | - Sarah Meister
- Department of Obstetrics and Gynaecology, Breast Center and CCCLMU, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany
| | - Christina Kuhn
- Department of Gynaecology and Obstetrics, University Hospital, Stenglinstr. 2, 86156, Augsburg, Germany
| | - Elisa Schmoeckel
- Department of Pathology, LMU Munich, Marchioninistr. 27, 81377, Munich, Germany
| | - Rachel Wuerstlein
- Department of Obstetrics and Gynaecology, Breast Center and CCCLMU, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany
| | - Nadia Harbeck
- Department of Obstetrics and Gynaecology, Breast Center and CCCLMU, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany
| | - Nina Ditsch
- Department of Gynaecology and Obstetrics, University Hospital, Stenglinstr. 2, 86156, Augsburg, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynaecology, Breast Center and CCCLMU, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany. .,Department of Gynaecology and Obstetrics, University Hospital, Stenglinstr. 2, 86156, Augsburg, Germany.
| | - Klaus Friese
- Department of Oncology, Hospital Bad Trissl, Bad-Trissl-Straße 73, 83080, Oberaudorf, Germany
| | - Theresa Maria Kolben
- Department of Obstetrics and Gynaecology, Breast Center and CCCLMU, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany
| |
Collapse
|
44
|
Deuster E, Hysenaj I, Kahaly M, Schmoeckel E, Mayr D, Beyer S, Kolben T, Hester A, Kraus F, Chelariu-Raicu A, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B. The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine. Cells 2021; 10:cells10092337. [PMID: 34571986 PMCID: PMC8466210 DOI: 10.3390/cells10092337] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 08/17/2021] [Accepted: 08/26/2021] [Indexed: 12/20/2022] Open
Abstract
The platelet-activating factor receptor (PAFR) and its ligand (PAF) are important inflammatory mediators that are overexpressed in ovarian cancer. The receptor is an important player in ovarian cancer development. In this study, we aimed to evaluate the prognostic value of PAFR in epithelial ovarian cancer (EOC) and the potential use of its antagonist, rupatadine, as an experimental treatment. Tissue microarrays of ovarian cancer patients, most markedly those with a non-mucinous subtype, immunohistochemically overexpressed PAFR. Elevated cytoplasmic PAFR expression was found to significantly and independently impair patients' overall and recurrence-free survival (OS: median 83.48 vs. 155.03 months; p = 0.022; RFS: median 164.46 vs. 78.03 months; p = 0.015). In vitro, the serous ovarian cancer subtypes especially displayed an elevated PAFR gene and protein expression. siRNA knockdown of PAFR decreased cell proliferation significantly, thus confirming the receptor's protumorigenic effect on ovarian cancer cells. The clinically approved PAFR antagonist rupatadine effectively inhibited in vitro cell proliferation and migration of ovarian cancer cells. PAFR is a prognostic marker in ovarian cancer patients and its inhibition through rupatadine may have important therapeutic implications in the therapy of ovarian cancer patients.
Collapse
Affiliation(s)
- Eileen Deuster
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
| | - Ivi Hysenaj
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
| | - Maja Kahaly
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
| | - Elisa Schmoeckel
- Institute of Pathology, Faculty of Medicine, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.S.); (D.M.)
| | - Doris Mayr
- Institute of Pathology, Faculty of Medicine, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.S.); (D.M.)
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
| | - Anna Hester
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
| | - Fabian Kraus
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
| | - Anca Chelariu-Raicu
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
| | - Alexander Burges
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
- Department of Obstetrics and Gynecology, University Hospital Augsburg, 86156 Augsburg, Germany
| | - Fabian Trillsch
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
| | - Bastian Czogalla
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU) Munich, 81377 Munich, Germany; (E.D.); (I.H.); (M.K.); (S.B.); (T.K.); (A.H.); (F.K.); (A.C.-R.); (A.B.); (S.M.); (U.J.); (F.T.)
- Correspondence:
| |
Collapse
|
45
|
Velotti P, Rogier G, Zobel SB, Ciavolino E, Beyer S, Fonagy P. Preliminary data on the psychometric proprieties of the italian version of the reflective functioning questionnaire. Eur Psychiatry 2021. [PMCID: PMC9475880 DOI: 10.1192/j.eurpsy.2021.1362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Assessing mentalizing abilities is a complex issue. Only recently an instrument assessing mentalizing capacity as a whole, the Reflective Functioning Questionnaire (RFQ), has been developed. Objectives To reach the purpose of our study, we investigated the psychometric proprieties of the Italian version of the RFQ. Methods The study was conducted on a sample including a group of violent offenders and a group of community participants. All subjects fulfilled the RFQ, the Personality Inventory for DSM-5 (PID-5) and the Aggression Questionnaire (AQ). Results The theoretical model was defined and analysed by using Partial Least Squares–Path Modelling with high-order construct definition. Data showed good psychometric proprieties of the Italian version of the RFQ. Also, specific patterns of correlations were identified between the RFQ subscales and both PID-5 and AQ scores. Offenders significantly differed from controls only in relation to one subscale of the RFQ. Conclusions Data supported the factorial structure of the RFQ found in the original validation study. Results also support the existence of a second-order variable, mentalizing, resulting from the convergence of hypomentalizing and hypermentalizing.
Collapse
|
46
|
Vilsmaier T, Amann N, Löb S, Schmoeckel E, Kuhn C, Zati Zehni A, Meister S, Beyer S, Kolben TM, Becker J, Mumm JN, Mahner S, Jeschke U, Kolben T. The decidual expression of Interleukin-7 is upregulated in early pregnancy loss. Am J Reprod Immunol 2021; 86:e13437. [PMID: 33934432 DOI: 10.1111/aji.13437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 04/01/2021] [Accepted: 04/12/2021] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND Maternal immunological rejection of the semi-allogenic fetus is discussed as one of the significant factors involved in early pregnancy loss. An array of cytokines secreted by both maternal and fetal cells is involved in generating a delicate maternal immune tolerance. Interleukin-7 (IL-7) is discussed to play a key role in pro-inflammatory processes, but there is still limited insight into the pathophysiological input on placentation and embryonic development in early pregnancy loss. PATIENTS AND METHODS Cytokine level differences were identified with quantitative real-time PCR in placental tissue from spontaneous abortions (SA) (n = 18), recurrent spontaneous abortions (RSA) (n = 15), and healthy pregnancies (n = 15) at gestational weeks 7 to 14. Protein expression of IL-7 in the decidua was investigated by immunohistochemistry. IL-7-expressing cells were identified with double-immunofluorescence. RESULTS Decidua of women with RSA expressed almost 51-times higher values of IL-7 in gene expression analysis. Immunohistochemistry identified a significant upregulation of IL-7 in the decidua of RSA specimens (p = .013) and in the decidua of women with SA (p = .004). Double-immunofluorescence confirmed decidual stroma cells as IL-7-expressing cells. CONCLUSION Significantly elevated IL-7 values in the decidua of spontaneous and recurrent miscarriages imply a crucial role of the cytokine in the signaling at the feto-maternal interface of the placenta. An overexpression of IL-7 could result in early pregnancy loss by inducing a pro-inflammatory environment. Proven to be valuable in other autoimmune diseases, targeting IL-7 signaling therapeutically may prove to be a very beneficial treatment option for RSA patients.
Collapse
Affiliation(s)
- Theresa Vilsmaier
- Department of Obstetrics and Gynecology, University Hospital Munich, LMU Munich, Germany
| | - Niklas Amann
- Department of Obstetrics and Gynecology, University Hospital Munich, LMU Munich, Germany
| | - Sanja Löb
- Department of Obstetrics and Gynecology, University Hospital Munich, LMU Munich, Germany.,Department of Obstetrics and Gynecology, University Hospital, University of Wuerzburg, LMU Munich, Germany
| | - Elisa Schmoeckel
- Department of Pathology, University Hospital, LMU Munich, Germany
| | - Christina Kuhn
- Department of Obstetrics and Gynecology, University Hospital Augsburg, LMU Munich, Germany
| | - Alaleh Zati Zehni
- Department of Obstetrics and Gynecology, University Hospital Munich, LMU Munich, Germany
| | - Sarah Meister
- Department of Obstetrics and Gynecology, University Hospital Munich, LMU Munich, Germany
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital Munich, LMU Munich, Germany
| | - Theresa M Kolben
- Department of Obstetrics and Gynecology, University Hospital Munich, LMU Munich, Germany
| | - Johanna Becker
- Department of Obstetrics and Gynecology, University Hospital Munich, LMU Munich, Germany
| | - Jan-Niclas Mumm
- Department of Urology, University Hospital, LMU Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital Munich, LMU Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital Munich, LMU Munich, Germany.,Department of Obstetrics and Gynecology, University Hospital Augsburg, LMU Munich, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital Munich, LMU Munich, Germany
| |
Collapse
|
47
|
Lin L, Kuhn C, Ditsch N, Kolben T, Czogalla B, Beyer S, Trillsch F, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Hester A. Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs). Breast Cancer Res 2021; 23:45. [PMID: 33849622 PMCID: PMC8042723 DOI: 10.1186/s13058-021-01422-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Accepted: 03/23/2021] [Indexed: 12/31/2022] Open
Abstract
Background An abundance of tumor-associated macrophages has been shown to be an independent prognostic factor for a poor prognosis of human breast cancer (BC). Adipose tissue accounts for the largest proportion of the breast and has also been identified as an independent indicator of poor survival in BC. This study aims to elucidate if the influence of adipose tissue in BC might be mediated by macrophages. The roles of macrophages in the breast tumor-stroma (breast tumor stroma macrophages, BTSM) and macrophages in the surrounding adipose tissue (breast adipose tissue macrophages, BATM) were explored separately. Methods Two hundred ninety-eight BC tissue samples were analyzed immunohistochemically. The number of macrophages was detected by CD68+ staining. The quantity of BATMs and BTSMs was correlated to clinical and pathological parameters as well as to disease-free survival (DFS) and overall survival (OS). Results The amounts of BATMs and BTSMs strongly correlated with each other (r = 0.5, p = 2.98E−15). The quantity of BTSMs, but not of BATMs, was significantly associated with the BC molecular subtype (p = 0.000011), and all triple-negative BC tumors contained high amounts of BTSMs. BATMs were negatively associated with DFS (p = 0.0332). Both BATMs (p = 0.000401) and BTSMs (p = 0.021) were negatively associated with OS in the Kaplan-Meier analysis, but only BATMs remained an independent factor in the multivariate Cox-regression analysis (HR = 4.464, p = 0.004). Combining prostaglandin E2 receptor 3 (EP3)-expression and the quantity of BATMs, a subgroup with an extremely poor prognosis could be identified (median OS 2.31 years in the “high BATMs/low EP3” subgroup compared to 11.42 years in the most favorable “low BATMs/high EP3” subgroup, p = 0.000002). Conclusion Our findings suggest that BTSMs and BATMs seem to be involved differently in BC. Breast adipose tissue might contribute to the aggressiveness of BC via BATMs, which were independently associated with BC survival. BATMs’ role and occurrence might be functionally dependent on EP3, as a combination of both factors was strongly associated with survival. Targeting BATMs—eventually in combination with targeting the EP3-pathway—might be promising for future therapies. Supplementary Information The online version contains supplementary material available at 10.1186/s13058-021-01422-x.
Collapse
Affiliation(s)
- Lili Lin
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Christina Kuhn
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.,Department of Obstetrics and Gynaecology, University Hospital Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany
| | - Nina Ditsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.,Department of Obstetrics and Gynaecology, University Hospital Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Bastian Czogalla
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Fabian Trillsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Elisa Schmoeckel
- Department of Pathology, LMU Munich, Thalkirchner Straße 36, 80337, Munich, Germany
| | - Doris Mayr
- Department of Pathology, LMU Munich, Thalkirchner Straße 36, 80337, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. .,Department of Obstetrics and Gynaecology, University Hospital Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany.
| | - Anna Hester
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| |
Collapse
|
48
|
Marx G, Bickenbach J, Fritsch SJ, Kunze JB, Maassen O, Deffge S, Kistermann J, Haferkamp S, Lutz I, Voellm NK, Lowitsch V, Polzin R, Sharafutdinov K, Mayer H, Kuepfer L, Burghaus R, Schmitt W, Lippert J, Riedel M, Barakat C, Stollenwerk A, Fonck S, Putensen C, Zenker S, Erdfelder F, Grigutsch D, Kram R, Beyer S, Kampe K, Gewehr JE, Salman F, Juers P, Kluge S, Tiller D, Wisotzki E, Gross S, Homeister L, Bloos F, Scherag A, Ammon D, Mueller S, Palm J, Simon P, Jahn N, Loeffler M, Wendt T, Schuerholz T, Groeber P, Schuppert A. Algorithmic surveillance of ICU patients with acute respiratory distress syndrome (ASIC): protocol for a multicentre stepped-wedge cluster randomised quality improvement strategy. BMJ Open 2021; 11:e045589. [PMID: 34550901 PMCID: PMC8039261 DOI: 10.1136/bmjopen-2020-045589] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
INTRODUCTION The acute respiratory distress syndrome (ARDS) is a highly relevant entity in critical care with mortality rates of 40%. Despite extensive scientific efforts, outcome-relevant therapeutic measures are still insufficiently practised at the bedside. Thus, there is a clear need to adhere to early diagnosis and sufficient therapy in ARDS, assuring lower mortality and multiple organ failure. METHODS AND ANALYSIS In this quality improvement strategy (QIS), a decision support system as a mobile application (ASIC app), which uses available clinical real-time data, is implemented to support physicians in timely diagnosis and improvement of adherence to established guidelines in the treatment of ARDS. ASIC is conducted on 31 intensive care units (ICUs) at 8 German university hospitals. It is designed as a multicentre stepped-wedge cluster randomised QIS. ICUs are combined into 12 clusters which are randomised in 12 steps. After preparation (18 months) and a control phase of 8 months for all clusters, the first cluster enters a roll-in phase (3 months) that is followed by the actual QIS phase. The remaining clusters follow in month wise steps. The coprimary key performance indicators (KPIs) consist of the ARDS diagnostic rate and guideline adherence regarding lung-protective ventilation. Secondary KPIs include the prevalence of organ dysfunction within 28 days after diagnosis or ICU discharge, the treatment duration on ICU and the hospital mortality. Furthermore, the user acceptance and usability of new technologies in medicine are examined. To show improvements in healthcare of patients with ARDS, differences in primary and secondary KPIs between control phase and QIS will be tested. ETHICS AND DISSEMINATION Ethical approval was obtained from the independent Ethics Committee (EC) at the RWTH Aachen Faculty of Medicine (local EC reference number: EK 102/19) and the respective data protection officer in March 2019. The results of the ASIC QIS will be presented at conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER DRKS00014330.
Collapse
Affiliation(s)
- Gernot Marx
- Department of Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
| | - Johannes Bickenbach
- Department of Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
| | - Sebastian Johannes Fritsch
- Department of Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Juelich Supercomputing Centre, Forschungszentrum Juelich GmbH, Juelich, Germany
| | - Julian Benedict Kunze
- Department of Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
| | - Oliver Maassen
- Department of Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
| | - Saskia Deffge
- Department of Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
| | - Jennifer Kistermann
- Department of Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
| | - Silke Haferkamp
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Division Information Technology, University Hospital Aachen, Aachen, Germany
| | - Irina Lutz
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Division Information Technology, University Hospital Aachen, Aachen, Germany
| | - Nora Kristiana Voellm
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Division Information Technology, University Hospital Aachen, Aachen, Germany
| | - Volker Lowitsch
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Healthcare IT Solutions GmbH, Aachen, Germany
| | - Richard Polzin
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Institute for Computational Biomedicine II, RWTH Aachen University, Aachen, Germany
| | - Konstantin Sharafutdinov
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Institute for Computational Biomedicine II, RWTH Aachen University, Aachen, Germany
| | - Hannah Mayer
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Systems Pharmacology & Medicine, Bayer AG, Leverkusen, Germany
| | - Lars Kuepfer
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Systems Pharmacology & Medicine, Bayer AG, Leverkusen, Germany
| | - Rolf Burghaus
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Systems Pharmacology & Medicine, Bayer AG, Leverkusen, Germany
| | - Walter Schmitt
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Clinical Pharmacometry, Bayer AG, Leverkusen, Germany
| | - Joerg Lippert
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Clinical Pharmacometry, Bayer AG, Leverkusen, Germany
| | - Morris Riedel
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Juelich Supercomputing Centre, Forschungszentrum Juelich GmbH, Juelich, Germany
| | - Chadi Barakat
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Juelich Supercomputing Centre, Forschungszentrum Juelich GmbH, Juelich, Germany
| | - André Stollenwerk
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Informatik 11 - Embedded Software, RWTH Aachen University, Aachen, Germany
| | - Simon Fonck
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Informatik 11 - Embedded Software, RWTH Aachen University, Aachen, Germany
| | - Christian Putensen
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Anesthesiology and Intensive Care Medicine, Universitätsklinikum Bonn, Bonn, Germany
| | - Sven Zenker
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Anesthesiology and Intensive Care Medicine, Universitätsklinikum Bonn, Bonn, Germany
- Staff Unit for Medical and Scientific Technology Development and Coordination, Commercial Directorate, University of Bonn Medical Center, Applied Medical Informatics, Institute for Biometrics, Informatics, and Epidemiology, University Hospital Bonn, Bonn, Germany
| | - Felix Erdfelder
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Anesthesiology and Intensive Care Medicine, Universitätsklinikum Bonn, Bonn, Germany
- Staff Unit for Medical and Scientific Technology Development and Coordination, Commercial Directorate, University of Bonn Medical Center, Applied Medical Informatics, Institute for Biometrics, Informatics, and Epidemiology, University Hospital Bonn, Bonn, Germany
| | - Daniel Grigutsch
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Anesthesiology and Intensive Care Medicine, Universitätsklinikum Bonn, Bonn, Germany
- Staff Unit for Medical and Scientific Technology Development and Coordination, Commercial Directorate, University of Bonn Medical Center, Applied Medical Informatics, Institute for Biometrics, Informatics, and Epidemiology, University Hospital Bonn, Bonn, Germany
| | - Rainer Kram
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Anesthesiology, University Hospital Dusseldorf, Dusseldorf, Germany
| | - Susanne Beyer
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- IT Department, University Hospital Dusseldorf, Dusseldorf, Germany
| | - Knut Kampe
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Jan Erik Gewehr
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Research IT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Friederike Salman
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Patrick Juers
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Research IT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Stefan Kluge
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Daniel Tiller
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- IT Department, Data Integration Center, University Hospital Halle, Halle, Germany
| | - Emilia Wisotzki
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- IT Department, Data Integration Center, University Hospital Halle, Halle, Germany
| | - Sebastian Gross
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Halle, Germany
| | - Lorenz Homeister
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Halle, Germany
| | - Frank Bloos
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany
| | - André Scherag
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital, Jena, Germany
| | - Danny Ammon
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- IT Department, Data Integration Center, Jena University Hospital, Jena, Germany
| | - Susanne Mueller
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital, Jena, Germany
| | - Julia Palm
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital, Jena, Germany
| | - Philipp Simon
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Anesthesiology and Intensive Care Medicine, University Hospital Leipzig, Leipzig, Germany
| | - Nora Jahn
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Anesthesiology and Intensive Care Medicine, University Hospital Leipzig, Leipzig, Germany
| | - Markus Loeffler
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany
| | - Thomas Wendt
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Data Integration Center, IT Department, University Hospital Leipzig, Leipzig, Germany
| | - Tobias Schuerholz
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Department of Anesthesiology and Intensive Care Medicine, Rostock University Medical Center, Rostock, Germany
| | - Petra Groeber
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- IT Department, Rostock University Medical Center, Rostock, Germany
| | - Andreas Schuppert
- SMITH consortium of the German Medical Informatics Initiative, Leipzig, Germany
- Institute for Computational Biomedicine II, RWTH Aachen University, Aachen, Germany
| |
Collapse
|
49
|
Patel S, Zhao S, Wei L, Li M, Bertino E, Presley C, Welliver M, Haglund K, Palmer J, Arnett A, Beyer S, Mende E, Elder J, Hardesty D, Shields P, Carbone D, Otterson G, Williams T, Owen D. P21.02 Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
50
|
Meister S, Hahn L, Beyer S, Kuhn C, Jegen M, von Schönfeldt V, Corradini S, Schulz C, Kolben TM, Hester A, Appelt T, Mahner S, Jeschke U, Kolben T. Epigenetic modification via H3K4me3 and H3K9ac in human placenta is reduced in preeclampsia. J Reprod Immunol 2021; 145:103287. [PMID: 33662848 DOI: 10.1016/j.jri.2021.103287] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Revised: 01/11/2021] [Accepted: 02/03/2021] [Indexed: 12/17/2022]
Abstract
BACKROUND Alterations of DNA accessibility and chromatin structure are associated with diseases. We aimed to investigate epigenetic modifications in preeclampsia (PE), a pregnancy-associated hypertonic disease. Specifically, we addressed histone modification proteins H3K9ac (acetylated lysine 9 of the histone H3) and H3K4me3 (trimethylated lysine 4 of the histone H3) in PE. METHODS We analyzed expression of histone proteins H3K4me3 and H3K9ac in 32 PE and 32 control placentas by immunohistochemistry. Further, we carried out confirmatory western blot analysis of respective proteins in 6 representative placentas. We then applied regression models with additional adjustment for potential confounders. RESULTS Expression of H3K4me3 and H3K9ac is reduced in PE placentas as demonstrated by immunohistochemical stainings and western blot. There are no differences between female and male fetuses in the presence of these histone modifications. H3K4me3 positively correlated with maternal age (r = 0.444, p = 0.034). CONCLUSION Expression of the placental histone proteins H3K4me3 and H3K9ac is reduced in PE, and independent of fetal gender. Our study underlines the involvement of epigenetic changes in the placenta of women suffering from PE.
Collapse
Affiliation(s)
- Sarah Meister
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Laura Hahn
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Susanne Beyer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Christina Kuhn
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Magdalena Jegen
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Viktoria von Schönfeldt
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Stefanie Corradini
- Department of Radiation Oncology, University Hospital, LMU, Munich, Marchioninistr. 15, 81377, Germany.
| | - Christian Schulz
- Medizinische Klinik und Poliklinik I, Klinikum der Universität, Ludwig-Maximilians-Universität, Marchioninistrasse 15, 81377, Munich, Germany.
| | - Theresa Maria Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Anna Hester
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Tamara Appelt
- Department of General and Visceral Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany; Department of Gynecology and Obstetrics, University Hospital Augsburg, 86156, Augsburg, Germany.
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| |
Collapse
|